Ashish M. Kamat, M.D., MBBS

Peer-Reviewed Articles

1. Makaroff LE, Filicevas A, Boldon S, Hensley P, Black PC, Chisolm S, Demkiw S, Fernández MI, Sugimoto M, Jensen BT, Witjes WPJ, Bagshaw K, Cirefice-Funk L, Knight A, Kamat AM. Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries. Eur Urol 84(2):248-251, 2023. e-Pub 2023. PMID: 37236857.
2. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. J Urol 210(2):101097JU0000000000003553, 2023. e-Pub 2023. PMID: 37211780.
3. Jubber I, Ong S, Bukavina L, Black PC, Compérat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks JJ, Moch H, Necchi A, Panebianco V, Sridhar SS, Znaor A, Catto JWF, Cumberbatch MG. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol 84(2):176-190, 2023. e-Pub 2023. PMID: 37198015.
4. Dyrskjøt L, Vlahou A, Black PC, Droller M, Grossmann HB, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Todenhöfer T, Williams SB, Schmitz-Dräger BJ. 25 years International Bladder Cancer Network (IBCN): The past, the present, and the future. Urol Oncol 41(7):302-306, 2023. e-Pub 2022. PMID: 36437158.
5. Christensen E, Wyatt AW, Galsky MD, Grivas P, Seiler R, Nawroth R, Goebell PJ, Schmitz-Drager BJ, Williams SB, Black PC, Kamat AM, Todenhöfer T, Dyrskjøt L. IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer. Urol Oncol 41(7):318-322, 2023. e-Pub 2022. PMID: 36437155.
6. Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol 20(7):406-419, 2023. e-Pub 2023. PMID: 36977797.
7. Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol 20(7):452, 2023. e-Pub 2023. PMID: 37217696.
8. Goebell PJ, Kamat AM, Black PC, Dyrskjøt L, Nawroth R, Seiler R, Todenhöfer T, Williams SB, Schmitz-Dräger BJ. Editorial: Cutting edge basic and clinical bladder cancer research - the IBCN updates. Urol Oncol 41(7):313-317, 2023. e-Pub 2023. PMID: 36641302.
9. Hensley PJ, Seiler R, Herr H, Mouw KW, Iyer G, Dyrskjøt L, Nawroth R, Goebell P, Schmitz-Drager B, Todenhofer T, Black PC, Kamat AM, Williams SB. Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1. Urol Oncol 41(7):307-312, 2023. e-Pub 2023. PMID: 36702704.
10. Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci 53:16-22, 2023. e-Pub 2023. PMID: 37441349.
11. Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of age >70?years on oncological outcomes in patients with NMIBC treated with BCG. BJU Int. e-Pub 2023. PMID: 37442564.
12. Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, Dinney CP, O'Donnell MA, Li R, Kamat AM, Packiam VT. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. e-Pub 2023. PMID: 37468392.
13. Koti M, Bivalacqua T, Black PC, Cathomen T, Galsky MD, Gulley JL, Ingersoll MA, Kamat AM, Kassouf W, Siemens DR, Gao J. Adaptive Immunity in Genitourinary Cancers. Eur Urol Oncol 6(3):263-272, 2023. e-Pub 2023. PMID: 37069029.
14. Beijert IJ, Cheng L, Liedberg F, Plass K, Williamson SR, Gontero P, Ribal MJ, Babjuk M, Black PC, Kamat AM, Algaba F, Berman DM, Hartmann A, Masson-Lecomte A, Rouprêt M, Lopez-Beltran A, Samaratunga H, Shariat SF, Mostafid AH, Varma M, Shen S, Burger M, Tsuzuki T, Palou J, Compérat EM, Sylvester RJ, van der Kwast TH, van Rhijn BWG, Downes MR. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members. Eur Urol Open Sci 52:154-165, 2023. e-Pub 2023. PMID: 37284047.
15. Crupi E, de Padua TC, Marandino L, Raggi D, Dyrskjøt L, Spiess PE, Sonpavde GP, Kamat AM, Necchi A. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol Oncol. e-Pub 2023. PMID: 37330413.
16. Tan WS, Hall E, Kamat AM, Kelly JD. Clinical trial design for non-muscle-invasive bladder cancer. Nat Rev Urol. e-Pub 2023. PMID: 37328547.
17. Paner GP, Kamat AM, Netto GJ, Samaratunga H, Varma M, Bubendorf L, van der Kwast TH, Cheng L, Members of the ISUP Bladder Tumor Consensus Panel. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. e-Pub 2023. PMID: 37382156.
18. Tan WS, Tan MY, Alhalabi O, Campbell MT, Kamat AM, Gao J. Evolving systemic management of urothelial cancers. Curr Opin Oncol 35(3):186-199, 2023. e-Pub 2023. PMID: 36966497.
19. Tan WS, Grajales V, Bree K, Li R, Nogueras-Gonzalez GM, Navai N, Dinney C, Kamat AM. BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?. BJU Int. e-Pub 2023. PMID: 37246493.
20. Reike MJ, Ingersoll MA, Müller DC, Zuiverloon TCM, Strandgaard T, Kamat AM, Williams SB, Seiler R, Todenhöfer T, Dyrskjøt L, Nawroth R, Goebell P, Schmitz-Dräger B, Sfakianos JP, Meeks J, Horowitz A, Black PC. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III. Urol Oncol 41(5):211-218, 2023. e-Pub 2022. PMID: 36266219.
21. Necchi A, Joshi M, Bangs R, Makaroff L, Grivas P, Kamat AM, Kassouf W, Raggi D, Marandino L, Krupski T, Flaig TW, Spiess PE, Global Society of Rare Genitourinary Tumors (GSRGT) and the International Bladder Cancer Group (IBCG). Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly. Clin Genitourin Cancer 21(2):301-308, 2023. e-Pub 2022. PMID: 36344399.
22. Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat AM, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2021. PMID: 34789422.
23. Hurle R, Soria F, Contieri R, Avolio PP, Mancon S, Lazzeri M, Bernasconi V, Mazzoli S, Pizzuto G, De Bellis M, Rosazza M, Livoti S, Lupia T, Corcione S, Lillaz B, De Rosa FG, Buffi NM, Kamat AM, Gontero P, Casale P. Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial. Cancers (Basel) 15(5), 2023. e-Pub 2023. PMID: 36900409.
24. Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol 41(2):108.e11-108.e17, 2023. e-Pub 2022. PMID: 36404232.
25. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol 209(1):140-149, 2023. e-Pub 2022. PMID: 36250944.
26. Zheng X, Kamat AM, Cao M, Kottapalli AGP. Wavy Whiskers in Wakes: Explaining the Trail-Tracking Capabilities of Whisker Arrays on Seal Muzzles. Adv Sci (Weinh) 10(2):e2203062, 2023. e-Pub 2022. PMID: 36403235.
27. Hensley PJ, Bree KK, Guo CC, Lobo N, Campbell MT, Pettaway CA, Kamat AM. Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. BJU Int 130(5):604-610, 2022. e-Pub 2021. PMID: 34773684.
28. Comperat E, Amin MB, Cathomas R, Choudhury A, Santis MD, Kamat AM, Stenzl A, Thoeny HC, Witjes JA. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. The Lancet, 2022. PMID: 36174585.
29. Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. e-Pub 2022. PMID: 35961847.
30. Agrawal P, Baraban E, de la Calle C, Patel S, Kamat AM, Smith A. Primary mesonephric adenocarcinoma of the bladder: A case report. Urol Case Rep 43:102096, 2022. e-Pub 2022. PMID: 35520026.
31. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB, Dinney CP, Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol 5(3):347-356, 2022. e-Pub 2021. PMID: 33935020.
32. Golla V, Shan Y, Farran EJ, Stewart CA, Vu K, Yu A, Khaki AR, Parikh DA, Swanson TA, Keegan KA, Kamat AM, Tyler DS, Freedland SJ, Williams SB. Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Urol Oncol 40(6):273.e1-273.e9, 2022. e-Pub 2022. PMID: 35168881.
33. Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol:101097JU0000000000002678. e-Pub 2022. PMID: 35770498.
34. Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. e-Pub 2022. PMID: 35718695.
35. Freudenburg E, Bagheri I, Srinivas S, Martinez A, Putluri N, Klaassen Z, Kamat AM, Konety BR, Kim WY, Dyrskjøt L, McConkey DJ, Freedland SJ, Black PC, Daneshmand S, Catto JWF, Williams SB. Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review. Cancer Causes Control. e-Pub 2022. PMID: 35699798.
36. Pohar KS, Patel S, Lotan Y, Trabulsi E, Woods M, Downs T, Huang WC, Jones J, Taylor J, O'Donnell M, Bivalacqua TJ, DeCastro J, Steinberg G, Kamat AM, Resnick MJ, Konety B, Schoenberg M, Jones JS, Daneshmand S, Flexible Blue Light Study Group Collaborators. Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. Urol Oncol. e-Pub 2022. PMID: 35750559.
37. Brooks NA, Kokorovic A, McGrath JS, Kassouf W, Collins JW, Black PC, Douglas J, Djaladat H, Daneshmand S, Catto JWF, Kamat AM, Williams SB. Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patient's undergoing urologic oncology surgery: a systematic review. World J Urol 40(6):1325-1342, 2022. e-Pub 2020. PMID: 32648071.
38. Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol 19(5):280-294, 2022. e-Pub 2022. PMID: 35361927.
39. Hensley PJ, Panebianco V, Pietzak E, Kutikov A, Vikram R, Galsky MD, Shariat S, Roupret M, Kamat AM. Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. Eur Urol Oncol. e-Pub 2022. PMID: 35581143.
40. Freudenburg E, Shan Y, Martinez A, Srinivasan A, Movva G, Yu A, AlBayyaa M, Klaassen Z, Freedland SJ, Kamat AM, Williams SB. Geographic distribution of racial differences in mortality in muscle-invasive bladder cancer patients: an opportunity for improvement. Cancer Causes Control 33(4):613-622, 2022. e-Pub 2022. PMID: 35050417.
41. Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 20(2):176-182, 2022. e-Pub 2021. PMID: 35039231.
42. Lobo N, Martini A, Kamat AM. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 22(4):1-10, 2022. e-Pub 2022. PMID: 35212590.
43. Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. e-Pub 2022. PMID: 35467000.
44. van der Kwast T, Liedberg F, Black PC, Kamat AM, van Rhijn BWG, Algaba F, Berman DM, Hartmann A, Lopez-Beltran A, Samaratunga H, Varma M, Cheng L. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus 8(2):438-446, 2022. e-Pub 2021. PMID: 33771477.
45. Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Ylä-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol 81(3):223-228, 2022. e-Pub 2021. PMID: 34933753.
46. Hensley PJ, Kamat AM. Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol 81(3):316-317, 2022. e-Pub 2022. PMID: 35039182.
47. Laukhtina E, Moschini M, Soria F, Andrea DD, Teoh JY, Mori K, Albisinni S, Mari A, Krajewski W, Cimadamore A, Abufaraj M, Enikeev D, Neuzillet Y, Giannarini G, Xylinas E, Kamat AM, Roupret M, Babjuk M, Witjes JA, Shariat SF, Pradere B, European Association of Urology, Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group, European Association of Urology Section of Oncological Urology ESOU. Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group. Eur Urol Focus. e-Pub 2022. PMID: 35337773.
48. Bree KK, Shan Y, Hensley PJ, Lobo N, Hu C, Tyler DS, Chamie K, Kamat AM, Williams SB. Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. JAMA Netw Open 5(3):e223050, 2022. e-Pub 2022. PMID: 35302627.
49. Khanna A, Miest T, Sharma V, Campbell R, Hensley P, Thapa P, Zganjar A, Tollefson MK, Thompson RH, Frank I, Karnes RJ, Murthy PB, Haber GP, Navai N, Kamat AM, Dinney C, Lee B, Boorjian SA. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. J Urol 207(3):551-558, 2022. e-Pub 2021. PMID: 34694143.
50. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Sylvester RJ, Kamat AM. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Eur Urol Oncol 5(1):84-91, 2022. e-Pub 2021. PMID: 34920986.
51. Williams SB, Gavaghan MB, Fernandez A, Daneshmand S, Kamat AM. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer. Urol Oncol 40(1):10.e7-10.e12, 2022. e-Pub 2021. PMID: 34158205.
52. Murakami K, Kamat AM, Dai Y, Pagano I, Chen R, Sun Y, Gupta A, Goodison S, Rosser CJ, Furuya H. Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. Cancer Biomark 33(1):151-157, 2022. e-Pub 2021. PMID: 34511488.
53. Chang E, Apolo AB, Bangs R, Chisolm S, Duddalwar V, Efstathiou JA, Goldberg KB, Hansel DE, Kamat AM, Kluetz PG, Lerner SP, Plimack E, Prowell T, Singh H, Suzman D, Yu EY, Zhang H, Beaver JA, Pazdur R, Weinstock C, Galsky MD. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol 19(1):37-46, 2022. e-Pub 2021. PMID: 34508246.
54. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B, European Association of Urology–Young Academic Urologists EAU-YAU Urothelial Carcinoma Working Group. Corrigendum to "Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis" [Eur Urol Oncol 2021;4:927-42]. Eur Urol Oncol. e-Pub 2022. PMID: 35063436.
55. Steinberg RL, Packiam VT, Thomas LJ, Brooks N, Vitale A, Mott SL, Crump T, Wang J, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol 40(1):9.e1-9.e7, 2022. e-Pub 2021. PMID: 34092482.
56. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2021. PMID: 35475152.
57. Hinestrosa JP, Kurzrock R, Lewis JM, Schork NJ, Schroeder G, Kamat AM, Lowy AM, Eskander RN, Perrera O, Searson D, Rastegar K, Hughes JR, Ortiz V, Clark I, Balcer HI, Arakelyan L, Turner R, Billings PR, Adler MJ, Lippman SM, Krishnan R. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med (Lond) 2:29, 2022. e-Pub 2022. PMID: 35603292.
58. Leow JJ, Tan WS, Tan WP, Tan TW, Chan VW, Tikkinen KAO, Kamat AM, Sengupta S, Meng MV, Shariat S, Roupret M, Decaestecker K, Vasdev N, Chong YL, Enikeev D, Giannarini G, Ficarra V, Teoh JY, UroSoMe Collaborators. A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond. Front Surg 9:879774, 2022. e-Pub 2022. PMID: 36268209.
59. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Should Patients With Non-Muscle-Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?. BJU Int. e-Pub 2021. PMID: 34854189.
60. Roumiguié M, Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, Böhle A, Brausi M, Buckley R, Persad R, Colombel M, Lamm D, Palou-Redorta J, Soloway M, Brothers K, Steinberg G, Lotan Y, Sylvester R, Alfred Witjes J, Black PC. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. e-Pub 2021. PMID: 34955291.
61. Lobo N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, Abraham P, Navai N, Dinney CP, Kamat AM. Reduced Dose BCG in an Era of BCG Shortage: Real-World Experience from a Tertiary Cancer Centre. BJU Int. e-Pub 2021. PMID: 34847263.
62. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B, European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. e-Pub 2021. PMID: 34753702.
63. Ekaterina Laukhtina, Sung Ryul Shim, Keiichiro Mori, David D‘Andrea, Francesco Soria, Pawel Rajwa, Hadi Mostafaei, Eva Comperat, Alessia Cimadamore, Marco Moschini, Jeremy Yuen-Chun Teoh, Dmitry Enikeev, Evanguelos Xylinas, Yair Lotanm, Juan Palou, Paolo Gontero, Marko Babjuk, J Alfred Witjes, Ashish M. Kamat , Morgan Roupret, Shahrokh F. Shariat, Benjamin Pradere, European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Accuracy of novel urinary biomarker tests for diagnosis and surveillance of NMIBC: A systematic review, diagnostic test accuracy and network meta-analyses. Eur Urol Oncol 33, Supplememt 3:S397-S398, 2021.
64. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke A, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma. BJUI Compass. e-Pub 2021.
65. Bree KK, Hensley PJ, Westerman ME, Kokorovic A, Nogueras-Gonzalez GM, Dinney CP, Kamat AM, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol 206(3):577-585, 2021. e-Pub 2021. PMID: 33872050.
66. Balar AV, Kamat AM, de Wit R, KEYNOTE-057 investigators. Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply. Lancet Oncol 22(9):e380, 2021. PMID: 34478664.
67. Hensley PJ, Kamat AM. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Implications for Clinical Trial Design. Reply. J Urol:101097JU0000000000002238. e-Pub 2021. PMID: 34520231.
68. Russo GI, Sholklapper TN, Cocci A, Broggi G, Caltabiano R, Smith AB, Lotan Y, Morgia G, Kamat AM, Witjes JA, Daneshmand S, Desai MM, Gill IS, Cacciamani GE. Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. Cancers (Basel) 13(17), 2021. e-Pub 2021. PMID: 34503188.
69. Galsky MD, Balar AV, Black PC, Campbell MT, Dykstra GS, Grivas P, Gupta S, Hoimes CJ, Lopez LP, Meeks JJ, Plimack ER, Rosenberg JE, Shore N, Steinberg GD, Kamat AM. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer 9(7), 2021. PMID: 34266883.
70. Bree KK, Brooks NA, Kamat AM. Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer. Hematol Oncol Clin North Am 35(3):513-529, 2021. e-Pub 2021. PMID: 33958148.
71. Westerman ME, Bree KK, Kokorovic A, Frank J, Wang XS, Kamat AM, Dinney CPN, Navai N. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology. e-Pub 2021. PMID: 34186127.
72. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after BCG Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol:101097JU0000000000001943. e-Pub 2021. PMID: 34184926.
73. Giannarini G, Agarwal N, Apolo AB, Briganti A, Grivas P, Gupta S, Kamat AM, Montorsi F, Rouprêt M, Necchi A. Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. e-Pub 2021. PMID: 34147473.
74. Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. e-Pub 2021. PMID: 34051177.
75. Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, Dyrskjøt L, Kamat AM. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. Eur Urol Oncol. e-Pub 2021. PMID: 33975782.
76. Kokorovic A, Westerman ME, Krause K, Hernandez M, Brooks N, Dinney CPN, Kamat AM, Navai N. Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. Bladder Cancer 7(2):243-252, 2021. e-Pub 2021. PMID: 34195319.
77. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Time Interval from Transurethral Resection of Bladder Tumor to BCG Induction Does Not Impact Therapeutic Response. BJU Int. e-Pub 2021. PMID: 33783950.
78. Hugar LA, Gilbert SM, Sexton WJ, Kamat AM, Li R. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol 31(2):160-169, 2021. PMID: 33394766.
79. Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, Bischoff R, Black PC, Boehm F, Céraline J, Chrousos GP, Delles C, Evenepoel P, Fridolin I, Glorieux G, van Gool AJ, Heidegger I, Ioannidis JPA, Jankowski J, Jankowski V, Jeronimo C, Kamat AM, Masereeuw R, Mayer G, Mischak H, Ortiz A, Remuzzi G, Rossing P, Schanstra JP, Schmitz-Dräger BJ, Spasovski G, Staessen JA, Stamatialis D, Stenvinkel P, Wanner C, Williams SB, Zannad F, Zoccali C, Vanholder R. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. Hypertension:HYPERTENSIONAHA12016340. e-Pub 2021. PMID: 33583200.
80. Baack Kukreja J, Li R, Narayan VM, Lim A, Seif MA, Wang X, Kamat A, Dinney CP, Navai N. Oncologic equipoise between robotic and open radical cystectomy. J Endourol. e-Pub 2021. PMID: 33619985.
81. Feldman AS, Kulkarni GS, Bivalacqua TJ, Black PC, Delacroix S, Lerner SP, Kamat AM, Kassouf W. Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer. Urol Oncol. e-Pub 2021. PMID: 33642229.
82. Mostafid H, Kamat AM, Daneshmand S, Palou J, Taylor JA, McKiernan J, Catto J, Babjuk M, Soloway M. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol 4(1):12-19, 2021. e-Pub 2020. PMID: 32684515.
83. Jazzar U, Bergerot CD, Shan Y, Wallis CJ, Freedland SJ, Kamat AM, Tyler DS, Baillargeon J, Kuo YF, Klaassen Z, Williams SB. Use of Psychotropic Drugs Among Older Patients with Bladder Cancer in the United States. Psychooncology. e-Pub 2021. PMID: 33507622.
84. Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design. J Urol:101097JU0000000000001633. e-Pub 2021. PMID: 33502236.
85. Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CP, Kamat AM. Impact of upper tract urothelial carcinoma on response to bcg in patients with non-muscle invasive bladder cancer. BJU Int. e-Pub 2021. PMID: 33484074.
86. Yang M, Georgieva MV, Bocharova I, Vembusubramanian M, Qian K, Guo A, Kamat AM. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis. Adv Ther. e-Pub 2021. PMID: 33543424.
87. Kukreja JB, Seif MA, Mery MW, Incalcaterra JR, Kamat AM, Dinney CP, Shah JB, Feeley TW, Navai N. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol. e-Pub 2020. PMID: 33308972.
88. Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranasinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AM. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. BJU Int. e-Pub 2020. PMID: 33210440.
89. Koti M, Ingersoll MA, Gupta S, Lam CM, Li X, Kamat AM, Black PC, Siemens DR. Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. Eur Urol Oncol 3(5):622-630, 2020. e-Pub 2020. PMID: 32967818.
90. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. e-Pub 2020. PMID: 33046869.
91. Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol 78(3):387-399, 2020. e-Pub 2020. PMID: 32143924.
92. Bagheri I, Shan Y, Klaassen Z, Kamat AM, Konety B, Mehta HB, Baillargeon JG, Srinivas S, Tyler DS, Swanson TA, Kaul S, Hollenbeck BK, Williams SB. Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. Urology. e-Pub 2020. PMID: 32980405.
93. Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, Sengupta S, Mostafid H, Kamat AM, Black PC, Shariat S, Babjuk M, Wong MC. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol. e-Pub 2020. PMID: 32972792.
94. Necchi A, Gallina A, Dyrskjøt L, Roupret M, Kamat AM, Spiess PE, Grivas P, Gibb EA, Briganti A, Montorsi F. Converging Roads to Early Bladder Cancer. Eur Urol 78(2):127-130, 2020. e-Pub 2020. PMID: 32197887.
95. Li R, Gilbert SM, Kamat AM. Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin. Eur Urol. e-Pub 2020. PMID: 32861573.
96. Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA, Roupret M, Kamat AM. What Is the Significance of Variant Histology in Urothelial Carcinoma?. Eur Urol Focus 6(4):653-663, 2020. e-Pub 2019. PMID: 31530497.
97. Hwang MJ, Kamat AM, Dinney CP, Czerniak B, Guo CC. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol 154(2):208-214, 2020. e-Pub 2020. PMID: 32253420.
98. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Willemse PM, Williams A, Zigeuner R, Horwich A. Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. Eur Urol 78(1):e48-e50, 2020. e-Pub 2020. PMID: 32446863.
99. Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol 78(1):29-42, 2020. e-Pub 2020. PMID: 32414626.
100. O'Connor E, Teh J, Kamat AM, Lawrentschuk N. Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?. Future Oncol 16(19):1323-1325, 2020. e-Pub 2020. PMID: 32406253.
101. Brooks NA, Narayan V, Hegarty PK, Zafirakis H, Han XY, Kamat AM. The role of the urologist, BCG vaccine administration, and SARS-CoV-2: An overview. BJUI Compass 1(3):87-92, 2020. e-Pub 2020. PMID: 32835353.
102. Westerman ME, Kokorovic A, Wang XS, Lim A, Garcia-Gonzalez A, Seif M, Wang R, Kamat AM, Dinney CPN, Navai N. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. J Sex Med. e-Pub 2020. PMID: 32713807.
103. Kamat AM, Lerner SP, O'Donnell M, Georgieva MV, Yang M, Inman BA, Kassouf W, Boorjian SA, Tyson MD, Kulkarni GS, Chang SS, Konety BR, Svatek RS, Balar A, Witjes JA. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Eur Urol Oncol 3(3):318-340, 2020. e-Pub 2020. PMID: 32201133.
104. Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupret M, Shariat S, Gontero P, van Rhijn B, Zigeuner R, Sylvester R, Comperat E, Burger M, Malavaud B, Soloway M, Williams S, Black P, Daneshmand S, Steinberg G, Brausi M, Catto J, Kamat AM. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. Eur Urol 77(6):669-670, 2020. e-Pub 2020. PMID: 32192815.
105. Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer. J Urol 203(5):101097JU0000000000000688, 2020. e-Pub 2019. PMID: 31821066.
106. Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urol Oncol. e-Pub 2020. PMID: 32430255.
107. Brooks N, Nagaraju S, Matulay J, Han XY, Kamat AM. Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage. Eur Urol Oncol. e-Pub 2020. PMID: 32475716.
108. Kamat AM, Gontero P, Palou J. How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?. Eur Urol Oncol 3(2):252-257, 2020. e-Pub 2019. PMID: 31307960.
109. Williams SB, Black PC, Dyrskjøt L, Seiler R, Schmitz-Dräger B, Nawroth R, Todenhöfer T, Kamat AM, Goebell PJ. Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Network. Eur Urol 77(4):e105-e106, 2020. e-Pub 2019. PMID: 31787429.
110. Matulay JT, Soloway M, Witjes JA, Buckley R, Persad R, Lamm DL, Boehle A, Palou J, Colombel M, Brausi M, Kamat AM. Risk Adapted Management of Low-Grade Bladder Tumors: Recommendations from the International Bladder Cancer Group. BJU Int 125(4):497-505, 2020. e-Pub 2020. PMID: 31950596.
111. Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, Nam K, Kapadia E, Frenkl T, Steinberg G. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol 16(10):507-516, 2020. e-Pub 2020. PMID: 32162533.
112. Hegarty PK, Sfakianos JP, Giannarini G, DiNardo AR, Kamat AM. COVID-19 and Bacillus Calmette-Guérin: What is the Link?. Eur Urol Oncol, 2020. e-Pub 2020. PMID: 32327396.
113. Jazzar U, Shan Y, Klaassen Z, Freedland SJ, Kamat AM, Raji MA, Masel T, Tyler DS, Baillargeon J, Kuo YF, Mehta HB, Bergerot CD, Williams SB. Impact of Alzheimer's disease and related dementia diagnosis following treatment for bladder cancer. J Geriatr Oncol, 2020. e-Pub 2020. PMID: 32354675.
114. Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney C, Navai N. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol 38(4):247-254, 2020. e-Pub 2020. PMID: 31953001.
115. Liem EIML, Oddens JR, Vernooij RWM, Li R, Kamat A, Dinney CP, Mengual L, Alcaraz A, Izquierdo L, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM. The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. J Urol 203(2):101097JU0000000000000566, 2020. e-Pub 2019. PMID: 31549936.
116. Li R, Kamat AM. Predictors of Response to Intravesical Therapy. Urol Clin North Am 47(1):23-33, 2020. PMID: 31757297.
117. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol 77(2):223-250, 2020. e-Pub 2019. PMID: 31753752.
118. Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG Unresponsive Trials. Clin Cancer Res 26(4):882-891, 2020. e-Pub 2019. PMID: 31712383.
119. Kukreja JB, Metcalfe MJ, Qiao W,Kamat AM, Dinney CPN, Navai N. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus 6(1):88-94, 2020. e-Pub 2018. PMID: 30033071.
120. Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol 37(12):2691-2698, 2019. e-Pub 2019. PMID: 30864005.
121. Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, Shariat SF, Witjes JA, Compérat EM. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol 2(6):625-642, 2019. e-Pub 2019. PMID: 31601522.
122. Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Vives Rivera FA, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Ann Oncol 30(11):1697-1727, 2019. e-Pub 2020. PMID: 31987079.
123. Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Vives Rivera FA, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol 30(11):1697-1727, 2019. PMID: 31740927.
124. Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World J Urol 37(10):2017-2029, 2019. e-Pub 2018. PMID: 30535583.
125. Soloway M, Matulay JT, Kamat AM. A Case for Risk-adapted Management of Low-grade Bladder Tumors. Eur Urol Oncol, 2019. e-Pub 2019. PMID: 31645295.
126. Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol:1-9. e-Pub 2019. PMID: 31670753.
127. Huo J, Ray-Zack MD, Shan Y, Chamie K, Boorjian SA, Kerr P, Jana B, Freedland SJ, Kamat AM, Mehta HB, Williams SB. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. Eur Urol Oncol 2(5):497-504, 2019. e-Pub 2018. PMID: 31411998.
128. Burger M, Kamat AM, McConkey D. Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?. Eur Urol Oncol. e-Pub 2019. PMID: 31395481.
129. Pignot G, Loriot Y, Kamat AM, Shariat SF, Plimack ER. Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. Eur Urol Oncol 2(4):355-364, 2019. e-Pub 2019. PMID: 31277773.
130. Matulay JT, Woldu SL, Lim A, Narayan VM, Li G, Kamat AM, Anderson CB. The impact of squamous histology on survival in patients with muscle-invasive bladder cancer. Urol Oncol 37(6):353.e17-353.e24, 2019. e-Pub 2019. PMID: 30704959.
131. Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB. Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. JAMA Surg:e191629, 2019. e-Pub 2019. PMID: 31166593.
132. Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. Nat Rev Urol 16(6):377-386, 2019. PMID: 31019310.
133. Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol 2(3):286-293, 2019. e-Pub 2018. PMID: 31200843.
134. Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE, Huang H, Dadhania V, Gao J, Dinney C, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep 27(6):1781-1793.e4, 2019. PMID: 31067463.
135. Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncol 15(12):1323-1334, 2019. e-Pub 2019. PMID: 30942088.
136. Maulhardt HA, Hylle L, Frost MV, Tornio A, Dafoe S, Drummond L, Quinn DI, Kamat AM, diZerega GS. Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. Cancers (Basel) 11(4), 2019. e-Pub 2019. PMID: 31022918.
137. Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. New horizons in bladder cancer research. Urol Oncol. e-Pub 2019. PMID: 30852032.
138. Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL. Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. Eur Urol Oncol 2(2):119-125, 2019. e-Pub 2018. PMID: 31017086.
139. Williams SB, Kamat AM, Mehta HB. Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer-Reply. JAMA Surg 154(2):186, 2019. e-Pub 2018. PMID: 30476959.
140. Matulay JT, Narayan VM, Kamat AM. Clinical and Genomic Considerations for Variant Histology in Bladder Cancer. Curr Oncol Rep 21(3):23, 2019. e-Pub 2019. PMID: 30806832.
141. Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol 37(1):3-13, 2019. e-Pub 2018. PMID: 30105454.
142. Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol 75(1):8-10, 2019. e-Pub 2018. PMID: 30301695.
143. Smith AB, Daneshmand S, Patel S, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Taylor J, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, Lotan Y, Flexible Blue Light Study Group Collaborators. Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. BJU Int 123(1):35-41, 2019. e-Pub 2018. PMID: 29979488.
144. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol 36(12):2027-2034, 2018. e-Pub 2018. PMID: 29804202.
145. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol 74(6):784-795, 2018. e-Pub 2018. PMID: 30268659.
146. Ray-Zack MD, Shan Y, Mehta HB, Yu X, Kamat AM, Williams SB. Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model. Urol Oncol, 2018. e-Pub 2018. PMID: 30446462.
147. Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF, Kulkarni GS. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. Eur Urol 74(5):597-608, 2018. e-Pub 2018. PMID: 30017405.
148. Williams SB, Shan Y, Jazzar U, Mehta HB, Baillargeon JG, Huo J, Senagore AJ, Orihuela E, Tyler DS, Swanson TA, Kamat AM. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. JAMA Surg 153(10):881-889, 2018. e-Pub 2018. PMID: 29955780.
149. Tabayoyong W, Kamat AM. Current Use and Promise of Urinary Markers for Urothelial Cancer. Curr Urol Rep 19(12):96, 2018. e-Pub 2018. PMID: 30328534.
150. Hermans TJN, Voskuilen CS, van der Heijden MS, Schmitz-Dräger BJ, Kassouf W, Seiler R, Kamat AM, Grivas P, Kiltie AE, Black PC, van Rhijn BWG. Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. Urol Oncol 36(9):413-422, 2018. e-Pub 2017. PMID: 29128420.
151. Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus 4(5):720-724, 2018. e-Pub 2017. PMID: 28753837.
152. Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM. Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. Urol Oncol 36(9):423-431, 2018. e-Pub 2018. PMID: 29496372.
153. Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Small cell carcinoma of the urinary bladder: a Clinicopathologic and Immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65, 2018. e-Pub 2018. PMID: 29763719.
154. Jazzar U, Yong S, Klaassen Z, Huo J, Hughes BD, Esparza E, Mehta HB, Kim SP, Tyler DS, Freedland SJ, Kamat AM, Wolf DV, Williams SB. Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer 124(15):3127-3135, 2018. e-Pub 2018. PMID: 29660813.
155. Flannery K, Cao X, He J, Zhong Y, Shah AY, Kamat AM. Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy. Clin Genitourin Cancer 16(4):e909-e917, 2018. e-Pub 2018. PMID: 29735397.
156. Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. Eur Urol Oncol 1(3):223-230, 2018. e-Pub 2018. PMID: 31102625.
157. Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. Eur Urol Oncol 1(3):190-198, 2018. e-Pub 2018. PMID: 31102620.
158. Black PC, Goebell PJ,Kamat AM, Nawroth R, Schmitz-Dräger BJ. New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017. Bladder Cancer 4(3):339-342, 2018. e-Pub 2018. PMID: 30112445.
159. Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB. Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Focus 4(4):512-521, 2018. e-Pub 2018. PMID: 30190111.
160. Kukreja JB, Shi Q, Chang CM, Seif MA, Sterling BM, Chen TY, Creel KM, Kamat AM, Dinney CP, Navai N, Shah JB, Wang XS. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov 25(3):1553350618764218, 2018. e-Pub 2018. PMID: 29557251.
161. Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, Shariat SF, Sylvester RJ, Gontero P. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol 73(6):925-933, 2018. e-Pub 2018. PMID: 29523366.
162. Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. Eur Urol Oncol 1(2):91-100, 2018. e-Pub 2018. PMID: 30345422.
163. Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, Flexible Blue Light Study Group Collaborators. Efficacy and Safety of Blue Light Flexible Cystoscopy With Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multi-Center Study. J Urol 199(5):1158-1165, 2018. e-Pub 2017. PMID: 29203268.
164. Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. Eur Urol 73(5):738-748, 2018. e-Pub 2017. PMID: 29055653.
165. Briganti A, Albiges L, Giannarini G, Kamat AM, Nguyen PL. Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers. Eur Urol Oncol 1(1):1-2, 2018. e-Pub 2018. PMID: 31100222.
166. Tabayoyong W, Li R, Gao J, Kamat A. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urol Clin North Am 45(2):155-167, 2018. e-Pub 2018. PMID: 29650132.
167. Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, Zlotta AR, Shariat SF. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. Eur Urol 73(4):543-557, 2018. e-Pub 2017. PMID: 29122377.
168. Li R, Spiess PE, Kamat AM. Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. Eur Urol, 2018. e-Pub 2018. PMID: 29685644.
169. Li R, Metcalfe MJ, Ferguson JE, Mokkapati S, Nogueras González GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121(2):244-251, 2018. e-Pub 2017. PMID: 28872778.
170. Guo CC, Al-Ahmadie HA, Flaig TW, Kamat AM. Contribution of bladder cancer pathology assessment in planning clinical trials. Urol Oncol, 2018. e-Pub 2018. PMID: 29395955.
171. Matulay JT, Kamat AM. Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Res 7, 2018. e-Pub 2018. PMID: 30109022.
172. Williams SB, Huo J, Chu Y, Baillargeon JG, Daskivich T, Kuo YF, Kosarek CD, Kim SP, Orihuela E, Tyler DS, Freedland SJ, Kamat AM. Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making. Urology 110:76-83, 2017. e-Pub 2017. PMID: 28847688.
173. Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus 3(6):577-583, 2017. e-Pub 2017. PMID: 28753816.
174. Lee EK, Kamat AM. Should we care more about SPARE?. BJU Int 120(5):605-606, 2017. PMID: 29035018.
175. Jinesh GG, Kamat AM. The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. Cancer Res 77(22):6144-6156, 2017. e-Pub 2017. PMID: 28855211.
176. Baack Kukreja J, Kamat AM. Strategies to minimize readmission rates following major urologic surgery. Ther Adv Urol 9(5):111-119, 2017. e-Pub 2017. PMID: 28588648.
177. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol 35(30):3410-3416, 2017. e-Pub 2017. PMID: 28834453.
178. Williams SB, Huo J, Dafashy TJ, Ghaffary CK, Baillargeon JG, Morales EE, Kim SP, Kuo YF, Orihuela E, Tyler DS, Freedland SJ, Kamat AM. Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment. Urol Oncol 35(10):602.e1-602.e9, 2017. e-Pub 2017. PMID: 28647395.
179. Williams SB, Kamat AM, Mmeje C, Ye Y, Huang M, Chang DW, Dinney CP, Wu X. Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin. Oncotarget 8(51):88782-88791, 2017. e-Pub 2017. PMID: 29179475.
180. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol 198(3):552-559, 2017. e-Pub 2017. PMID: 28456635.
181. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 5(1):80, 2017. e-Pub 2017. PMID: 28962591.
182. Wang G, Huang H, Kamat AM, Siefker-Radtke A, Dinney CP, Troncoso P, Czerniak B, Guo CC. High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol 67:126-133, 2017. e-Pub 2017. PMID: 28823575.
183. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. J Oncol Pract 13(9):621-625, 2017. e-Pub 2017. PMID: 28796558.
184. Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol 31(9):946-953, 2017. e-Pub 2017. PMID: 28731777.
185. Jinesh GG, Manyam GC, Mmeje CO, Baggerly KA, Kamat AM. Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep 7(1):9602, 2017. e-Pub 2017. PMID: 28851898.
186. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 5(1):68, 2017. e-Pub 2017. PMID: 28807024.
187. Williams SB, Huo J, Kosarek CD, Chamie K, Rogers SO, Williams MA, Giordano SH, Kim SP, Kamat AM. Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer. Cancer Causes Control 28(7):755-766, 2017. e-Pub 2017. PMID: 28477210.
188. Huo J, Chu Y, Chamie K, Smaldone MC, Boorjian SA, Baillargeon JG, Kuo YF, Kerr P, O'Malley P, Orihuela E, Tyler DS, Freedland SJ, Giordano SH, Vikram R, Kamat AM, Williams SB. Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed with Bladder Cancer. Clin Genitourin Cancer, 2017. PMID: 28826932.
189. Flaig TW, Kamat AM, Hansel D, Ingersoll MA, Barton Grossman H, Mendelsohn C, DeGraff D, Liao JC, Taylor JA. Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium. Bladder Cancer 3(3):211-223, 2017. e-Pub 2017. PMID: 28824949.
190. Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, O'Donnell M, Quale DZ. Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer 3(3):145-146, 2017. e-Pub 2017. PMID: 28824940.
191. Myers AL, Zhang YP, Kawedia JD, Zhou X, Sobocinski SM, Metcalfe MJ, Kramer MA, Dinney CPN, Kamat AM. Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs R D 17(2):297-304, 2017. PMID: 28470465.
192. Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Zhang L, Dinney CP, Czerniak B, Guo CC. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol 147(5):500-506, 2017. e-Pub 2017. PMID: 28371875.
193. Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int 119(5):684-691, 2017. e-Pub 2016. PMID: 27753185.
194. Taoka R, Jinesh GG, Xue W, Safe S, Kamat AM. CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program. Apoptosis 22(5):719-729, 2017. PMID: 28283889.
195. Jinesh GG, Kamat AM. RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program. Cell Death Discov 3:17023, 2017. e-Pub 2017. PMID: 28580172.
196. Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, Buckley R, Persad R, Palou J, Soloway M, Witjes JA. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol 14(4):244-255, 2017. e-Pub 2017. PMID: 28248951.
197. Pan Q, Sathe A, Black PC, Goebell PJ, Kamat AM, Schmitz-Draeger B, Nawroth R. CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer. Bladder Cancer 3(2):79-88, 2017. e-Pub 2017. PMID: 28516152.
198. Williams SB, Huo J, Chamie K, Hu JC, Giordano SH, Hoffman KE, Dinney CPN, Kamat AM, Shih YT. Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. Eur Urol Focus 3(2-3):258-264, 2017. e-Pub 2016. PMID: 28753760.
199. Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, Raman JD, Seitz C, Xylinas E, Shariat SF. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol 35(3):337-353, 2017. e-Pub 2016. PMID: 27101100.
200. Jinesh GG, Kamat AM. Blebbishields and mitotic cells exhibit robust macropinocytosis. Biofactors 43(2):181-186, 2017. e-Pub 2016. PMID: 27671897.
201. Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, Kamat AM. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology 6(2):e1265719, 2017. e-Pub 2017. PMID: 28344874.
202. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet 388(10061):2796-2810, 2016. e-Pub 2016. PMID: 27345655.
203. Mmeje CO, Guo CC, Shah JB, Navai N, Grossman HB, Dinney CP, Kamat AM. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. Eur Urol 70(5):778-785, 2016. e-Pub 2016. PMID: 26922408.
204. Parker WP, Ho PL, Boorjian SA, Melquist JJ, Thapa P, Holzbeierlein JM, Frank I, Kamat AM, Lee EK. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. World J Urol 34(11):1561-1566, 2016. e-Pub 2016. PMID: 26943643.
205. Navai N, Benedict WF, Zhang G, Abraham A, Ainslie N, Shah JB, Grossman HB, Kamat AM, Dinney CP. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol 23(12):4110-4114, 2016. e-Pub 2016. PMID: 27387678.
206. Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol 70(4):611-620, 2016. e-Pub 2016. PMID: 26988609.
207. Kassouf W, Traboulsi SL, Schmitz-Dräger B, Palou J, Witjes JA, van Rhijn BW, Grossman HB, Kiemeney LA, Goebell PJ, Kamat AM. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations. Urol Oncol 34(10):460-8, 2016. e-Pub 2016. PMID: 27368880.
208. Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA. Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. Urol Oncol 34(10):437-51, 2016. e-Pub 2016. PMID: 27641313.
209. Vlahou A, Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Taking the next step-Advancing bladder cancer management. Urol Oncol 34(10):435-6, 2016. PMID: 27658683.
210. Takeuchi H, Taoka R, Mmeje CO, Jinesh GG, Safe S, Kamat AM. CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. Urol Oncol 34(8):337.e11-8, 2016. e-Pub 2016. PMID: 27038699.
211. Oshiro H, Czerniak BA, Sakamaki K, Tsuta K, Bondaruk J, Keyhani A, Dinney CP, Nagai T, Kamat AM. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. Medicine (Baltimore) 95(31):e4500, 2016. PMID: 27495099.
212. Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol 34(16):1935-44, 2016. e-Pub 2016. PMID: 26811532.
213. Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-González G, Katz RL, Wu X, Barton Grossman H, Dinney CP. A novel FISH-based definition of BCG failure to enhance recruitment into clinical trials of intravesical therapies. BJU Int 117(5):754-60, 2016. e-Pub 2015. PMID: 26032953.
214. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol 69(5):855-62, 2016. e-Pub 2015. PMID: 26343003.
215. Donovan FX, Kimble DC, Kim Y, Lach FP, Harper U, Kamat AM, Jones M, Sanborn EM, Tryon R, Wagner JE, MacMillan ML, Ostrander EA, Auerbach AD, Smogorzewska A, Chandrasekharappa SC. Paternal or Maternal Uniparental Disomy of Chromosome 16 Resulting in Homozygosity of a Mutant Allele Causes Fanconi Anemia. Hum Mutat 37(5):465-8, 2016. e-Pub 2016. PMID: 26841305.
216. Jinesh GG, Kamat AM. Blebbishield emergency program: an apoptotic route to cellular transformation. Cell Death Differ 23(5):757-8, 2016. e-Pub 2016. PMID: 26967969.
217. Jinesh GG, Taoka R, Zhang Q, Gorantla S, Kamat AM. Novel PKC-ζ to p47(phox) interaction is necessary for transformation from blebbishields. Sci Rep 6:23965, 2016. e-Pub 2016. PMID: 27040869.
218. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer 2(2):165-202, 2016. e-Pub 2016. PMID: 27376138.
219. Kamat AM, Cookson M, Witjes JA, Stenzl A, Grossman HB. The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis. Bladder Cancer 2(2):273-278, 2016. e-Pub 2016. PMID: 27376146.
220. Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, Garcia-Closas M, Chatterjee N, Koutros S, Kiemeney LA, Rafnar T, Bishop T, Furberg H, Matullo G, Golka K, Gago-Dominguez M, Taylor JA, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang Z, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M, Teo M, Offit K, Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Sacerdote C, Selinski S, Hengstler JG, Gerullis H, Ovsiannikov D, Blaszkewicz M, Castelao JE, Calaza M, Martinez ME, Cordeiro P, Xu Z, Panduri V, Kumar R, Gurzau E, Koppova K, Bueno-De-Mesquita HB, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Jeppson RP, Cancel-Tassin G, Roupret M, Comperat E, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang L, Gong Y, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Monawar Hosain GM, Schwenn M, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Andriole G, Grubb R, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF, Vineis P, Wu X, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet 25(6):1203-14, 2016. e-Pub 2016. PMID: 26732427.
221. Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R, Grossman HB, Prat F, Dinney CP. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. Eur Urol 69(2):197-200, 2016. e-Pub 2015. PMID: 26119560.
222. Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, Tart K, Parikh S, Shah JB, Delacroix SE, Navai N, Siefker-Radtke A, Dinney CP, Pisters LL, Kamat AM. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol 34(2):59.e1-8, 2016. e-Pub 2015. PMID: 26421586.
223. Jinesh GG, Molina JR, Huang L, Laing NM, Mills GB, Bar-Eli M, Kamat AM. Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis. Cell Death Discov 2:16003, 2016. PMID: 27551498.
224. Jinesh GG, Laing NM, Kamat AM. Smac mimetic with TNF-α targets Pim-1 isoforms and reactive oxygen species production to abrogate transformation from blebbishields. Biochem J 473(1):99-107, 2016. e-Pub 2015. PMID: 26508734.
225. Jinesh GG, Kamat AM. Endocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells. Cell Death Discov 2, 2016. e-Pub 2016. PMID: 27226900.
226. Pierzynski JA, Hildebrandt MA, Kamat AM, Lin J, Ye Y, Dinney CP, Wu X. Genetic Variants in the Wnt/β-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. J Urol 194(6):1771-6, 2015. e-Pub 2015. PMID: 26173102.
227. Dhillon J, Liang Y, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol 46(12):1808-14, 2015. e-Pub 2015. PMID: 26364859.
228. Takeuchi H, Mmeje CO, Jinesh GG, Taoka R, Kamat AM. Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells. Oncol Rep 34(5):2738-44, 2015. e-Pub 2015. PMID: 26323344.
229. Morales A, Kamat AM, Steinberg G, Given R, Amrhein J, Cohen Z, Herr H. Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4). Urol Oncol 33(8):335-6, 2015. PMID: 26182846.
230. Williams SB, Ye Y, Huang M, Chang DW, Kamat AM, Pu X, Dinney CP, Wu X. Mitochondrial DNA Content as Risk Factor for Bladder Cancer and its Association with Mitochondrial DNA Polymorphisms. Cancer Prev Res (Phila) 8(7):607-13, 2015. e-Pub 2015. PMID: 25896234.
231. Parker WP, Ho PL, Melquist JJ, Scott K, Holzbeierlein JM, Lopez-Corona E, Kamat AM, Lee EK. The Effect of Concomitant Carcinoma In Situ on Neoadjuvant Chemotherapy for Urothelial Cell Carcinoma of the Bladder: Inferior Pathological Outcomes but No Effect on Survival. J Urol 193(5):1494-9, 2015. e-Pub 2014. PMID: 25451834.
232. Breen V, Kasabov N, Kamat AM, Jacobson E, Suttie JM, O'Sullivan PJ, Kavalieris L, Darling DG. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Med Res Methodol 15:45, 2015. e-Pub 2015. PMID: 25962444.
233. Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AM. Clinical Outcomes in cT1 Micropapillary Bladder Cancer. J Urol 193(4):1129-34, 2015. e-Pub 2014. PMID: 25254936.
234. Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, Kamat AM. Efficacy and Safety of MCNA in Patients with Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and Progression who Have Failed Treatment with Bacillus Calmette-Guérin. J Urol 193(4):1135-43, 2015. e-Pub 2014. PMID: 25286009.
235. Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol 12(4):225-35, 2015. e-Pub 2015. PMID: 25800393.
236. Taoka R, Williams SB, Ho PL, Kamat AM. In-vitro cytocidal effect of water on bladder cancer cells: The potential role for intraperitoneal lavage during radical cystectomy. Can Urol Assoc J 9(3-4):E109-13, 2015. PMID: 25844095.
237. Lerner SP, Dinney C, Kamat AM, Bivalacqua TJ, Nielsen M, O'Donnell M, Schoenberg MP, Steinberg G. Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. Bl Cancer 1(1):29-30, 2015. PMID: 26807434.
238. Ho PL, Williams SB, Kamat AM. Immune therapies in non-muscle invasive bladder cancer. Curr Treat Options Oncol 16(2):315, 2015. PMID: 25757877.
239. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A,Kaaks R, Kamat AM,Kamineni A,Karagas M, Khanna C, Khaw KT, Kim C, Kim IS,Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC,. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet 23(24):6616-33, 2014. e-Pub 2014. PMID: 25027329.
240. Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol 142(6):864-71, 2014. PMID: 25389341.
241. Svatek RS, Clinton TN, Wilson CA, Kamat AM, Grossman HB, Dinney CP, Shah JB. Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy. Urology 84(5):1147-51, 2014. e-Pub 2014. PMID: 25174656.
242. Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat AM. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol 32(7):1061-8, 2014. e-Pub 2014. PMID: 24411790.
243. Goebell PJ, Kamat AM, Sylvester RJ, Black P, Droller M, Godoy G, Hudson MA, Junker K, Kassouf W, Knowles MA, Schulz WA, Seiler R, Schmitz-Dräger BJ. Assessing the quality of studies on the diagnostic accuracy of tumor markers. Urol Oncol 32(7):1051-60, 2014. e-Pub 2014. PMID: 25159014.
244. Kamat AM, Lamm DL. Predicting response to bacillus calmette-guérin: time to look beyond the ages. Eur Urol 66(4):702-3, 2014. e-Pub 2014. PMID: 24968969.
245. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, Schoenberg MP, Steinberg GD. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol 11(10):589-96, 2014. e-Pub 2014. PMID: 25245244.
246. Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. Urol Oncol 32(7):1069-77, 2014. e-Pub 2014. PMID: 25306288.
247. Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M. Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo-Controlled Trial. Eur Urol 66(2):265-72, 2014. e-Pub 2014. PMID: 24630419.
248. Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Böhle A, Colombel M, Palou J. Defining and Treating the Spectrum of Intermediate-Risk NMIBC. J Urol 192(2):305-15, 2014. e-Pub 2014. PMID: 24681333.
249. Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: Current treatment patterns and review of the literature. Urol Oncol 32(6):826-32, 2014. e-Pub 2014. PMID: 24931270.
250. Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol 45(7):1466-72, 2014. e-Pub 2014. PMID: 24745616.
251. Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martin C, Moreno J, Kamat AM. Alvimopan, a Peripherally Acting Mu-Opioid Receptor Antagonist, Is Associated with Reduced Costs After Radical Cystectomy-Economic Analysis of a Phase 4 Randomized, Controlled Trial. J Urol 191(6):1721-7, 2014. e-Pub 2013. PMID: 24342144.
252. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794-9, 2014. e-Pub 2014. PMID: 24633966.
253. Pisters AL, Kamat AM, Wei W, Leibovici D, Liu J, Grossman HB, Butler CE. Anterior fascial fixation does not reduce the parastomal hernia rate after radical cystectomy and ileal conduit. Urology 83(6):1427-32, 2014. e-Pub 2014. PMID: 24768021.
254. Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM. Clinical Significance of Ureteral "Skip Lesions" at the Time of Radical Cystectomy: the MD Anderson Experience and Review of Literature. BJU Int 113(5b):E28-33, 2014. e-Pub 2013. PMID: 24053608.
255. Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 83(4):863-8, 2014. e-Pub 2014. PMID: 24485993.
256. Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys 88(5):1048-56, 2014. PMID: 24661658.
257. Onaiwu CO, Ramirez PT, Kamat AM, Pagliaro LC, Euscher EE, Schmeler KM. Invasive extramammary Paget's disease of the bladder diagnosed 18 years after noninvasive extramammary Paget's disease of the vulva. Gynecol Oncol Case Rep 8:27-9, 2014. e-Pub 2014. PMID: 24809008.
258. Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue M, Jacobs EJ, Albanes D, Wang Z, Deng X, Chung CC, Tang W, Bas Bueno-de-Mesquita H, Trichopoulos D, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis R, Tjønneland A, Brenan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Lerner SP, Barton Grossman H, Lin J, Gu J, Pu X, Hutchinson A, Burdette L, Wheeler W, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Schwenn M, Karagas MR, Johnson A, Schned A, Armenti KR, Hosain GM, Andriole G, Grubb R, Black A, Ryan Diver W, Gapstur SM, Weinstein SJ, Virtamo J, Haiman CA, Landi MT, Caporaso N, Fraumeni JF, Vineis P, Wu X, Silverman DT, Chanock S, Rothman N. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 23(5):1387-98, 2014. e-Pub 2013. PMID: 24163127.
259. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining Patient Selection for Neoadjuvant Chemotherapy Prior to Radical Cystectomy. J Urol 191(1), 2014. PMID: 23911605.
260. Lamm D, Persad R, Brausi M, Buckley R, Witjes JA, Palou J, Böhle A, Kamat AM, Colombel M, Soloway M. Defining Progression in Non-Muscle Invasive Bladder Cancer (NMIBC): It's Time for a New, Standard Definition. J Urol 191(1):20-7, 2014. e-Pub 2013. PMID: 23973937.
261. Jinesh G G, Lee EK, Tran J, Kamat AM. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo. Urol Oncol 31(8), 2013. PMID: 22717623.
262. Fernández MI, Gong Y, Ye Y, Lin J, Chang DW, Kamat AM, Wu X. Gamma-H2AX Level in Peripheral Blood Lymphocytes as a Risk Predictor for Bladder Cancer. Carcinogenesis 34(11):2543-7, 2013. e-Pub 2013. PMID: 23946494.
263. Abel EJ, Fisher MB, Matin SF, Kamat AM, Dinney CP, Grossman HB. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol 39(6):817-22, 2013. PMID: 24456786.
264. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists(☆). Urol Oncol 31(7):1171-7, 2013. e-Pub 2012. PMID: 22534087.
265. Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, Persad R, Buckley R, Colombel M, Böhle A. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 112(6):742-50, 2013. e-Pub 2013. PMID: 23452187.
266. Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF. Phase I Trial of Intravesical Recombinant Adenovirus-Mediated Interferon-α2b Formulated in Syn3 for BCG failures in Non-Muscle-Invasive Bladder Cancer. J Urol 190(3):850-6, 2013. e-Pub 2013. PMID: 23507396.
267. Lee EK, Jinesh G G, Laing NM, Choi W, McConkey DJ, Kamat AM. A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biol Ther 14(9):812-22, 2013. e-Pub 2013. PMID: 23792592.
268. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM, Bladder Cancer Think Tank, Bladder Cancer Advocacy Network. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol 31(6):812-26, 2013. e-Pub 2011. PMID: 22056403.
269. Wang J, Wu X, Kamat AM, Barton Grossman H, Dinney CP, Lin J. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br J Cancer 108(11):2372-80, 2013. e-Pub 2013. PMID: 23632476.
270. Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, Schoenberg MP, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol 31(4):480-6, 2013. e-Pub 2011. PMID: 21478035.
271. Lee EK, Ye Y, Kamat AM, Wu X. Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer 119(9):1643-51, 2013. e-Pub 2013. PMID: 23529717.
272. Chauhan S, Goodwin JG, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD. ZKSCAN3 Is a Master Transcriptional Repressor of Autophagy. Mol Cell 50(1):16-28, 2013. e-Pub 2013. PMID: 23434374.
273. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results. Cancer 119(3):540-7, 2013. e-Pub 2012. PMID: 22914978.
274. Davis JW, Kamat AM. Lymphadenectomy with robotic cystectomy. Curr Urol Rep 14(1):Feb;14(1):59-63, 2013. PMID: 23138180.
275. Jinesh GG, Choi W, Shah JB, Lee EK, Willis DL, Kamat AM. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ 20(3):382-95, 2013. PMID: 23175184.
276. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. Eur Urol 63(1):4-15, 2013. e-Pub 2012. PMID: 23083902.
277. Lynch SP, Shen Y, Kamat AM, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A.. Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center. Eur Urol 64(2):307-13, 2013. PMID: 22564397.
278. Wei H, Kamat AM, Aldousari S, Ye Y, Huang M, Dinney CP, Wu X.. Genetic variations in the transformation growth factor Beta pathway as predictors of bladder cancer risk. PLoS One 2(12), 2012. PMID: 23251617.
279. Fernández MI, Parikh S, Grossman HB, Katz R, Matin SF, Dinney CP, Kamat AM. The role FISH and cytology in upper urinary tract surveillance after radical cystectomoy for bladder cancer. Urol Oncol 30(6):821-4, 2012. e-Pub 2011. PMID: 21396845.
280. Dickstein RJ, Nitti G, Dinney CP, Davies BR, Kamat AM, McConkey DJ. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther 13(13):1325-38, 2012. e-Pub 2012. PMID: 22895070.
281. Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol 30(6):772-8, 2012. PMID: 23218068.
282. Jinesh G G, Kamat AM. Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. Oncoimmunology 1(7):1161-1162, 2012. PMID: 23170264.
283. Wei H, Kamat AM, Chen M, Ke HL, Chang DW, Yin J, Grossman HB, Dinney CP, Wu X. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with bacillus calmette-guérin. PLoS One 7(6):e38533, 2012. PMID: 22701660.
284. Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PG, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek R. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World J. Urol 30(6):807-14, 2012. PMID: 22832587.
285. Lee EK, Herr HW, Dickstein RJ, Kassouf W, Munsell MF, Grossman HB, Dinney CP, Kamat AM. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvent therapies after radical cystectomy. BJU Int 110(11):590-5, 2012. PMID: 22758775.
286. Jinesh G G, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol 92(1):233-44, 2012. PMID: 22517918.
287. Sundi D, Svatek RS, Margulis V, Wood CG, Matin SF, Dinney CP, Kamat AM. Upper tract urothelial carcinoma: Impact of time to surgery. Urol Oncol 30(3):266-72, 2012. e-Pub 2010. PMID: 20869888.
288. Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP. Use of flourescence in situ hybridization to predict response to bacillus calmette-guerin therapy for bladder cancer: results of a prespective trial. J Urol 187(3):862-7, 2012. e-Pub 2012. PMID: 22245325.
289. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M, Kamat AM, Lerner SP, Grossman HB, Gu J, Pu X, Hutchinson A, Fu YP, Burdett L, Yeager M, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Fraumeni JF, Silverman DT, Chanock SJ, Wu X. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 20(21):4282-9, 2011. e-Pub 2011. PMID: 21824976.
290. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 108(7):1119-23, 2011. e-Pub 2011. PMID: 21426474.
291. Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78(1):61-7, 2011. e-Pub 2011. PMID: 21354598.
292. Gu J, Chen M, Shete S, Amos CI, Kamat AM, Ye Y, Lin J, Dinney CP, Wu X. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) 4(4):514-21, 2011. e-Pub 2011. PMID: 21460395.
293. Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol 29(2):157-61, 2011. e-Pub 2010. PMID: 20456984.
294. Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 107(6):898-904, 2011. e-Pub 2011. PMID: 21244604.
295. Davis JW, Gaston K, Anderson R, Dinney CP, Grossman HB, Munsell MF, Kamat AM. Robot Assisted Extended Pelvic Lymphadenectomy at Radical Cystectomy: Lymph Node Yield Compared with Second Look Open Dissection. J Urol 185(1):79-83, 2011. e-Pub 2010. PMID: 21074799.
296. Momoh AO, Kamat AM, Butler CE. Reconstruction of the pelvic floor with human acellular dermal matrix and omental flap following anterior pelvic exenteration. J Plast Reconstr Aesthet Surg 63(12):2185-7, 2010. e-Pub 2010. PMID: 20399719.
297. Svatek RS, Fisher MB, Williams MB, Matin SF, Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Dinney CP. Age and Body Mass Index Are Independent Risk Factors for the Development of Postoperative Paralytic Ileus After Radical Cystectomy. Urology 76(6):1419-24, 2010. e-Pub 2010. PMID: 20472264.
298. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther 10(9):885-92, 2010. e-Pub 2010. PMID: 20814238.
299. Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL, Zhang HZ, Kamat AM, Katz RL. Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol 118(5):259-68, 2010. e-Pub 2010. PMID: 20665656.
300. Xu AD, Ng CS, Kamat AM, Grossman HB, Dinney C, Sandler CM. Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. AJR Am J Roentgenol 195(4):959-65, 2010. PMID: 20858825.
301. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non-Muscle-Invasive Bladder Cancer. Cancer Prev Res (Phila) 3(10):1235-45, 2010. e-Pub 2010. PMID: 20858759.
302. Matin SF, Kamat AM, Grossman HB. High-frequency endoluminal ultrasonography as an aid to the staging of upper tract urothelial carcinoma: imaging findings and pathologic correlation. J Ultrasound Med 29(9):1277-84, 2010. PMID: 20733182.
303. Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL. Management of urethral recurrence after orthotopic urinary diversion. BJU Int 106(1):56-61, 2010. e-Pub 2009. PMID: 20002676.
304. Matin SF, Margulis V, Kamat AM, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127-34, 2010. PMID: 20564621.
305. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105(10):1402-12, 2010. e-Pub 2010. PMID: 20132195.
306. Carthon BC, Wolchok JD, Yuan J, Kamat AM, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 2010. e-Pub 2010. PMID: 20460488.
307. Davis JW, Kamat AM, Munsell M, Pettaway C, Pisters L, Matin S. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized?. BJU Int 105(8):1148-54, 2010. e-Pub 2009. PMID: 19874300.
308. Chiong E, Hegarty PK, Davis JW, Kamat AM, Pisters LL, Matin SF. Port-site Hernias Occurring After the Use of Bladeless Radially Expanding Trocars. Urology 75(3):574-80, 2010. e-Pub 2009. PMID: 19854489.
309. Cho SD, Lee SO, Chintharlapalli S, Abdelrahim M, Khan S, Yoon K, Kamat AM, Safe S. Activation of Nerve Growth Factor-Induced B{alpha} by Methylene-Substituted Diindolylmethanes in Bladder Cancer Cells Induces Apoptosis and Inhibits Tumor Growth. Mol Pharmacol 77(3):396-404, 2010. e-Pub 2009. PMID: 20023005.
310. Svatek RS, Fisher MB, Matin SF,Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Kennedy KA, Dinney CP. Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria. J Urol 183(3):929-34, 2010. e-Pub 2010. PMID: 20083264.
311. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat AM, Dinney CP, Lotan Y, Shariat SF. Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. Eur Urol 57(2):300-9, 2010. e-Pub 2009. PMID: 19766384.
312. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM. Curcumin Potentiates the Antitumor Effects of Gemcitabine in an Orthotopic Model of Human Bladder Cancer through Suppression of Proliferative and Angiogenic Biomarkers. Biochem Pharmacol 79(2):218-28, 2010. e-Pub 2009. PMID: 19682434.
313. Inamoto T, Czerniak BA, Dinney CP, Kamat AM. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer 2(116):340-346, 2010. PMID: 19908257.
314. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat AM, Zlotta A. An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer. Eur Urol 57(1):60-70, 2010. e-Pub 2009. PMID: 19740595.
315. Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 69(23):8958-66, 2009. e-Pub 2009. PMID: 19903839.
316. Fisher MB, Svatek RS, Hegarty PK, McGinniss JE, Hightower C, Grossman HB, Kamat AM, Dinney CP, Matin SF. Cardiac history and risk of post-cystectomy cardiac complications. Urology 74(5):1085-9, 2009. e-Pub 2009. PMID: 19758689.
317. Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat AM, Bassett R, Dinney CP, Czerniak BA. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol 40(10):1448-52, 2009. e-Pub 2009. PMID: 19454359.
318. Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, deVere White R, Quale D, Lee CT. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 115(18):4096-103, 2009. PMID: 19536899.
319. Lin J, Kamat AM, Gu J, Chen M, Dinney CP, Forman MR, Wu X. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev 18(7):2090-7, 2009. e-Pub 2009. PMID: 19549811.
320. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer. J Clin Oncol 27(16):2592-7, 2009. e-Pub 2009. PMID: 19414678.
321. Jain M, Matin SF, Kamat AM. Inferior Vena Cava Atresia Associated with von Hippel-Lindau Masquerading as Metastatic Testicular Cancer. Curr Urol 2(4):214-216, 2009. e-Pub 2009.
322. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2009. e-Pub 2009. PMID: 19202079.
323. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 115(6):1310-7, 2009. e-Pub 2009. PMID: 19156903.
324. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Wood CG. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115(6):1224-33, 2009. e-Pub 2009. PMID: 19156917.
325. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1):147-52, 2009. e-Pub 2008. PMID: 18848348.
326. Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther 7(12):3825-33, 2008. PMID: 19074857.
327. Liakou CI, Kamat AM, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105(39):14987-92, 2008. e-Pub 2008. PMID: 18818309.
328. Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic Urethral Biopsy Has Limited Usefulness in Counseling Patients Regarding Final Urethral Margin Status During Orthotopic Neobladder Reconstruction. J Urol 180(1):164-7; discussion 167, 2008. e-Pub 2008. PMID: 18485384.
329. Cárdenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting LS. Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study. Int Urol Nephrol 40(4):893-9, 2008. e-Pub 2008. PMID: 18317944.
330. Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 26(1):121-6, 2008. PMID: 18165646.
331. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant transformation of testicular teratoma: A chemoresistant phenotype. Urol Oncol 26(6):595-9, 2008. e-Pub 2008. PMID: 18367105.
332. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin SF, Kamat AM, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III Prevention Trial of Fenretinide in Patients with Resected Non Muscle-Invasive Bladder Cancer. Clin Cancer Res 14(1):224-229, 2008. PMID: 18172274.
333. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?. Cancer 110(12):2700-2708, 2007. PMID: 17948916.
334. Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol 178(6):2302-2306, 2007. e-Pub 2007. PMID: 17936803.
335. Caraway NP, Khanna A, Payne L, Kamat AM, Katz RL. Combination of cytologic evaluation and quantitative digital cytometry is reliable in detecting recurrent disease in patients with urinary diversions. Cancer 111(5):323-329, 2007. e-Pub 2007. PMID: 17721991.
336. Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner SP, Wu X, Gu J. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 28(10):2160-2165, 2007. e-Pub 2007. PMID: 17728339.
337. Jhamb M, Lin J, Ballow R, Kamat AM, Grossman HB, Wu X. Urinary tract diseases and bladder cancer risk: a case-control study. Cancer Causes Control 18(8):839-45, 2007. PMID: 17593531.
338. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 70(2):252-6, 2007. PMID: 17826484.
339. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer 110(4):764-9, 2007. PMID: 17614317.
340. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-7, 2007. PMID: 17542024.
341. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol 177(4):1330-4; discussion 1334, 2007. PMID: 17382725.
342. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6(3):1022-30, 2007. PMID: 17363495.
343. Kamat AM, Wu X. Statins and the effect of BCG on bladder cancer. N Engl J Med 356(12):1276; author reply 1276-7, 2007. PMID: 17377172.
344. Black PC, Kassouf W, Brown GA, Liu P, Kamat AM, Nogueras GM, Munsell MF, Siefker-Radtke A, Millikan RE, Grossman HB, Dinney CP. Variant histology in bladder cancer-experience in 1246 patients undergoing cystectomy. J Urol 177(4):502, 2007.
345. Spiess PE, Tannir NM, Brown GA, Liu P, Kamat AM. Recurrence in patients with PNO at RPLND: can we predict which patients are at risk?. J Urol 177(4):330, 2007.
346. Spiess PE, Brown GA, Tannir NM, Tu Shi-Ming, Liu P, Kamat AM. Predicting disease progression in patients with viable tumor at post-chemotherapy rplnd. JUrol 177(4):278, 2007.
347. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 177(1):131-8, 2007. PMID: 17162023.
348. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol 25(1):38-45, 2007. PMID: 17208137.
349. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. Eur Urol 52(3):769-776, 2007. PMID: 17434254.
350. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?. BJU Int 98(6):1176-80, 2006. PMID: 17125474.
351. Papageorgiou A, Kamat AM, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5(12):3032-41, 2006. PMID: 17172406.
352. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176(4 Pt 1):1463-7, 2006. PMID: 16952661.
353. Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM. Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol 176(4 Pt 1):1642-7, 2006. PMID: 16952707.
354. Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, Kamat AM. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer 107(7):1491-5, 2006. PMID: 16894527.
355. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7):1483-90, 2006. PMID: 16944541.
356. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?. Cancer 107(7):1503-10, 2006. PMID: 16944534.
357. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107(3):631-9, 2006. PMID: 16802288.
358. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 176(1):53-7; discussion 57, 2006. PMID: 16753366.
359. Rosser CJ, Kamat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, Babaian RJ. Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. Cancer 107(1):54-9, 2006. PMID: 16708356.
360. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 175(6):2058-62, 2006. PMID: 16697803.
361. Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanches-Ortiz RF, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology 67(4):769-73, 2006. e-Pub 2006. PMID: 16584762.
362. Canfield SE, Kamat AM, Sánchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175(3 Pt 1):864-9, 2006. PMID: 16469567.
363. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology 67(3):518-23, 2006. PMID: 16527570.
364. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(3 Pt 1):881-5, 2006. PMID: 16469571.
365. Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?. Urology 67(3):466-71, 2006. PMID: 16527559.
366. Dhanani NN, Kamat AM. Treatment of bladder cancer in cardiac transplant patients. Int Urol Nephrol 38(3-4):477-9, 2006. PMID: 17115247.
367. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 66(1):412-8, 2006. PMID: 16397256.
368. Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66(6):1209-12, 2005. PMID: 16360444.
369. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-90, 2005. PMID: 16280761.
370. Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen S, Babaian RJ. Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol 174(4 Pt 1):1262-5, 2005. PMID: 16145389.
371. Mohamedali KA, Kedar D, Sweeney P, Kamat AM, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 7(10):912-20, 2005. PMID: 16242074.
372. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 63(1):134-40, 2005. PMID: 16111581.
373. Shapiro A, Vakar F, Kamat AM. Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guerin instillation masquerading as peritoneal carcinomatosis. Urol Oncol 23(5):352-3, 2005. PMID: 16144670.
374. Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer?. Urology 66(2):327-31, 2005. PMID: 16040084.
375. Kamat AM, Carpenter SM, Czerniak BA, Pisters LL. Metastatic penile cancer in a young Caucasian male: impact of delayed diagnosis. Urol Oncol 23(2):130-1, 2005. PMID: 15869998.
376. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat AM, Pisters L, Kuban D. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with. Int J Radiat Oncol Biol Phys 61(4):993-1002, 2005. PMID: 15752878.
377. Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 62(1):101-4, 2005. PMID: 15389800.
378. Cheung R, Tucker SL, Lee AL, Dong L, Kamat AM, Pisters L, Kuban DA. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(1):14-19, 2005. PMID: 15629589.
379. Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 96(7):939-44, 2004. PMID: 15253325.
380. Kamat AM, Rosser CJ, Levy LB, Chichakli R, Lee AK, Cheung MR, Pisters LL. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63(6):1132-7, 2004. PMID: 15183966.
381. Kamat AM, Plager C, Tamboli P, Tran N, Pettaway CA. Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha. J Urol 171(5):1886-7, 2004. PMID: 15076299.
382. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3(3):279-90, 2004. PMID: 15026548.
383. Kamat AM, Lamm DL. Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63(3):457-60, 2004. PMID: 15028437.
384. Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63(1):46-50, 2004. PMID: 14751346.
385. Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol 170(5):1860-3, 2003. PMID: 14532793.
386. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau D, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5):1868-71, 2003. PMID: 14532795.
387. Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 170(5):1856-9, 2003. PMID: 14532792.
388. Karashima T, Sweeney P, Kamat AM, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, Dinney CP. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 9(7):2786-97, 2003. PMID: 12855659.
389. Kamat AM, York T, Debord J. Anastomotic fistula after ileal loop urinary diversion presenting as persistent urethral drainage. J Urol 165(3):906-907, 2001. PMID: 11176505.
390. Kamat AM, DeHaven JI, Lamm DL. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54(1):56-61, 1999. PMID: 10414727.

Invited Articles

1. Li R, Baack Kukreja JE, Kamat AM. Secondary Tumors After Urinary Diversion. Urol Clin North Am 45(1):91-99, 2018. PMID: 29169454.
2. Ferguson JE, Kamat AM. It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis. Urol Oncol. e-Pub 2017. PMID: 29158136.
3. Kamat AM, Bagcioglu M, Huri E. What is new in non-muscle-invasive bladder cancer in 2016?. Turk J Urol 43(1):9-13, 2017. e-Pub 2017. PMID: 28270945.
4. Grossman HB, Lamm DL, Kamat AM, Keefe S, Taylor JA, Ingersoll MA. Innovation in Bladder Cancer Immunotherapy. J Immunother 39(8):291-7, 2016. PMID: 27428265.
5. Li R, Choi W, Ferguson Rd JE, Metcalfe MJ, Kamat AM. New discoveries in the molecular landscape of bladder cancer. F1000Res 5:2875, 2016. e-Pub 2016. PMID: 28105319.
6. Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am 29(2):237-52, viii, 2015. e-Pub 2015. PMID: 25836932.
7. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol 33(2):53-64, 2015. e-Pub 2014. PMID: 25065704.
8. Nawroth R, Goebell PJ, Kamat AM, Kiemeney LA, Schmitz-Dräger BJ. Current concepts--future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012. Urol Oncol 32(7):1049-50, 2014. e-Pub 2014. PMID: 25443142.
9. Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. e-Pub 2014. PMID: 24921905.
10. Jinesh GG, Willis DL, Kamat AM. Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives. Curr Stem Cell Res Ther. e-Pub 2013. PMID: 24236543.
11. Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y. Summary of the 6th annual bladder cancer think tank: New directions in urologic research. Urol Oncol 31(7):968-73, 2013. e-Pub 2012. PMID: 22300756.
12. Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer?. Curr Opin Urol 23(5):435-43, 2013. e-Pub 2013. PMID: 23880739.
13. Shah JB, Kamat AM. Strategies for optimizing bacillus calmette-guerin. Urol Clin North Am 40(2):211-8, 2013. PMID: 23540779.
14. Kamat AM. Is repeat transurethral resection needed for minimally invasive t1 urothelial cancer?. J Urol 186(3):788-9, 2011. e-Pub 2011. PMID: 21794877.
15. Kamat AM, Mathew P. Bladder cancer: imperatives for personalized medicine. Oncology (Williston Park) 25(10):951-8, 960, 2011. PMID: 22010395.
16. Dickstein RJ, Kamat AM. Contemporary management of locally invasive bladder cancer. Oncology (Williston Park) 25(14):1396-405, 2011. PMID: 22329191.
17. Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM. Bladder cancer stem cells. Curr Stem Cell Res Ther 5(4):387-95, 2010. PMID: 20955163.
18. Kassouf W, Kamat AM, Zlotta A, Bochner BH, Moore R, So A, Izawa J, Rendon RA, Lacombe L, Aprikian AG. Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. Can Urol Assoc J 4(3):168-73, 2010. PMID: 20514279.
19. Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y. BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. Urol Oncol 28(3):334-7, 2010. PMID: 20439033.
20. Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol 28(3):338-42, 2010. PMID: 20439034.
21. Kamat AM, Lotan YR. Perioperative intravesical therapy after transurethral resection for bladder cancer. J Urol 183(1):19-20, 2010. PMID: 19913827.
22. Karam JA, Kamat AM. Optimal timing of chemotherapy and cystectomy. F1000 Med Rep 2, 2010. e-Pub 2010. PMID: 20948836.
23. Inamoto T, Shah JB, Kamat AM. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urol Oncol 27(6):585-91, 2009. e-Pub 2009. PMID: 19162510.
24. Svatek RS, Kamat AM, Dinney CP. Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 9(6):807-13, 2009. PMID: 19496717.
25. Martin FM, Kamat AM. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 9(6):815-20, 2009. PMID: 19496718.
26. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat AM, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28(3-4):335-44, 2009. PMID: 20012924.
27. Hegarty PK, Kamat AM. Management of bladder cancer. Minerva Urol Nefrol 60(4):255-64, 2008. PMID: 18923362.
28. La Rochelle J, Kamat AM, Grossman HB, Pantuck A. Chemoprevention of bladder cancer. BJU Int 102(9 Pt B):1274-8, 2008. PMID: 19035892.
29. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol 26(1):39-44, 2008. e-Pub 2007. PMID: 18092171.
30. Agarwal PK, Kamat AM. Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer. Indian J Urol 24(1):77-83, 2008. PMID: 19468365.
31. Kamat AM, Dinney CP. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol 3(9):472-3, 2006. PMID: 16964186.
32. Metwalli AR, Kamat AM. Controversial issues and optimal management of stage T1G3 bladder cancer. Expert Rev Anticancer Ther 6(8):1283-94, 2006. PMID: 16925494.
33. Busby JE, Kamat AM. Chemoprevention for bladder cancer. J Urol 176(5):1914-20, 2006. PMID: 17070211.
34. Brassell SA, Kamat AM. Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the bladder. J Natl Compr Canc Netw 4(10):1027-1036, 2006. PMID: 17112451.
35. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2):111-6, 2004. PMID: 15324694.
36. Herring JC, Kamat AM. Treatment of muscle-invasive bladder cancer: progress and new challenges. Expert Rev Anticancer Ther 4(6):1047-1056, 2004. PMID: 15606332.
37. Kassouf W, Kamat AM. Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 4(6):1283-1294, 2004. PMID: 15606331.
38. Kamat AM. Chemoprevention of superficial bladder cancer. Expert Rev Anticancer Ther 3(6):799-808, 2003. PMID: 14686702.
39. Kamat AM, Dinney CPN. Molecular aspects of metastases in bladder cancer. Urol Integ 8(2):180-189, 2003.
40. Kamat AM, Lamm DL. Chemoprevention of bladder cancer. Urol Clin North Am 29(1):1-12, 2002. PMID: 12109342.
41. Kamat AM, Lamm DL. Immunotherapy for bladder cancer. Curr Urol Rep 2(1):62-69, 2001. PMID: 12084297.
42. Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology 55(2):161-168, 2000. PMID: 10688071.
43. Kamat AM, Lamm DL. Current trends in intravesical therapy for bladder cancer. Contemporary Urology 12(8):64-88, 2000.
44. Kamat AM, Lamm DL. Diet and nutrition in urologic cancer. W V Med J 96(3):449-454, 2000. PMID: 14619137.
45. Kamat AM, Lamm DL. Chemoprevention of urological cancer. J Urol 161(6):1748-60, 1999. PMID: 10332429.
46. Kamat AM, Lamm DL. Role of BCG in treatment of superficial bladder cancer. Indian Journal of Urology 16(1):1-9, 1999.
47. Kamat AM, Lamm DL. Intravesical therapy for superficial bladder cancer. Inf Urol 12(2):37-45, 1999.

Manuals, Teaching Aids, Other Teaching Publications

1. Kamat AM. When to Use Intravesical Therapy for Bladder Cancer. Renal & Urology News, 2007.
2. Kamat AM. Prostate Cancer Guidelines. HealthGate: Burlington, MA, 2005.
3. Kamat AM. Bladder Cancer Options - State of the Art Patient Care, 2005.
4. Kamat AM. BCG Immunotherapy: Bladder Cancer and Beyond. CME Supplement to "Renal & Urology News", 2004.

Other Articles

1. Kamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor J, Williams SB, Quale DZ, Rosenberg JE Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer 2(2):203-213, 2016. PMID: 27376139.
2. Kamat AM, Hrabovsky EE Imperforate anus: an unusual presentation of a common disease. W V Med J 95(6):305-6, 1999. PMID: 10650775.

Editorials

1. van der Kwast T, Van Rhijn B, Kamat AM Cheng L. Reply to Rodolfo Montironi, Marina Scarpelli, Alessia Cimadamore, and Gregor Mikuz's Letter to the Editor re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017. Focus on Our Personal Recollections and Observations. Eur Urol Focus 8(3):885-886, 2022. PMID: 33992577.
2. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol:101097JU000000000000194302. PMID: 34372685.
3. Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Reply by Authors. J Urol 205(6):pp 1620-1621. PMID: 33734859.
4. Seiler R, Black PC, Williams SB, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series. Urol Oncol 37(11):815-817, 2019. PMID: 31377169.
5. Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1. Urol Oncol. PMID: 30683454.
6. Kamat AM, Gontero P. Editorial comment. Curr Opin Urol 28(6):555-556, 2018. PMID: 30256260.
7. Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urol Oncol. PMID: 29548621.
8. Kamat AM. Bladder cancer: 2017 and beyond. Indian J Urol 33(2):104-105, Apr-Jun, 2017. PMID: 28469296.
9. Morales EE, Aggarwal BB, Kamat AM. Natural Compounds Targeting STAT3 Mediated Inflammation. Eur Urol 69(3):405-6, 2016. PMID: 26454706.
10. Williams SB, Kamat AM. Optimal Management of Non-Muscle Invasive Micropapillary Variant Urothelial Carcinoma: Possibility For Missed Chance at Cure?. BJU Int. PMID: 26917454.
11. Kamat AM. Commentary on "Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy." Lee JY, Diaz RR, Cho KS, Lim MS, Chung JS, Kim WT, Ham WS, Choi YD, Department of Urology, Yonsei University College of Medicine, Seoul, Republic of Korea; Severance Hospital and Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.: J Urol 2013; 190(4):1192-9. doi:10.1016/j.juro.2013.04.077. [Epub 2013 May 3]. Urol Oncol 33(1):46, 2015. PMID: 25528637.
12. Kamat AM. Commentary on "The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: Results of a prospective, randomized, phase II trial." Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F.: J Urol 2013; 190(3):857-62. doi:10.1016/j.juro.2013.03.097. [Epub 2013 Mar 29]. Urol Oncol 33(1):46-7, 2015. PMID: 25528638.
13. Kamat AM. Commentary on "Impact of statin use on oncologic outcomes in patients with urothelial carcinoma ofthe bladder treated with radical cystectomy." da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, Guglielmetti GB, Pycha A, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Zerbib M, Scherr DS, Shariat SF, Department of Urology and Division of Medical Oncology, Weill Cornell Medical College, New York - Presbyterian Hospital, New York, New York 10065, USA.: J Urol 2013; 190(2):487-92. doi:10.1016/j.juro.2013.02.003. [Epub 2013 Feb 8]. Urol Oncol 33(1):47-8, 2015. PMID: 25528639.
14. Williams SB, Kamat AM, Lamm DL. Pelvic Recurrence Following Radical Cystectomy: A Call to Arms. BJU Int. PMID: 25307493.
15. Thomas AZ, Kamat AM. Venous thromboembolism and bleeding risk in bladder cancer. Oncology (Williston Park) 28(10):854-5, 861, 2014. PMID: 25323611.
16. Kamat AM, Porten S. Myths and Mysteries Surrounding Bacillus Calmette-Guérin Therapy for Bladder Cancer. Eur Urol. PMID: 24199712.
17. Kamat AM. Commentary on "Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition." Ros MM, Bueno-de-Mesquita HB, Kampman E, Aben KK, Büchner FL, Jansen EH, van Gils CH, Egevad L, Overvad K, Tjønneland A, Roswall N, Boutron-Ruault MC, Kvaskoff M, Perquier F, Kaaks R, Chang-Claude J, Weikert S, Boeing H, Trichopoulou A, Lagiou P, Dilis V, Palli D, Pala V, Sacerdote C, Tumino R, Panico S, Peeters PH, Gram IT, Skeie G, Huerta JM, Barricarte A, Quirós JR, Sánchez MJ, Buckland G, Larrañaga N, Ehrnström R, Wallström P, Ljungberg B, Hallmans G, Key TJ, Allen NE, Khaw KT, Wareham N, Brennan P, Riboli E, Kiemeney LA, National Institute for Public Health and the Environment, Bilthoven, Netherlands: Am J Clin Nutr 2012;96(4):902-10 [Epub 2012 Sep 5]. Urol Oncol 31(5):714-5, 2013. PMID: 23796198.
18. Kamat AM. Commentary on "The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature." Swietek N, Waldert M, Rom M, Schatzl G, Wiener HG, Susani M, Klatte T. Department of Urology, Medical University of Vienna, Vienna, Austria: J Urol 2012;188(3):748-53 [Epub 2012 Jul 20]. Urol Oncol 31(5):715-6, 2013. PMID: 23796199.
19. Kamat AM. Commentary on "Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome." Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Clendenning M, Rosty C, Arnold J, Levine AJ, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Hopper JL, Jenkins MA, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Victoria, Australia: J Natl Cancer Inst 2012;104(18):1363-72 [Epub 2012 Aug 28]. Urol Oncol 31(5):716, 2013. PMID: 23796201.
20. Kamat AM. Commentary on "Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience." Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W. Department of Surgery (Urology), McGill University, Quebec, Canada: BJU Int 2012;110(9):1317-23 [Epub 2012 Apr 13]. Urol Oncol 31(5):717-8, 2013. PMID: 23796202.
21. Kamat AM. Commentary on "Carboplatin based induction chemotherapy for nonorgan confined bladder cancer-a reasonable alternative for cisplatin unfit patients?" Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108-13 [Epub 2012 Aug 15]. Urol Oncol 31(5):716-7, 2013. PMID: 23796200.
22. Kamat AM. Commentary on "Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder." Mayr R, May M, Martini T, Lodde M, Pycha A, Comploj E, Wieland WF, Denzinger S, Otto W, Burger M, Fritsche HM. Department of Urology, Central Hospital of Bolzano, Bolzano, Italy: BJU Int 2012;110(6 Pt B):E222-7 [Epub 2012 Feb 7]. Urol Oncol 31(5):718-9, 2013. PMID: 23796203.
23. Kamat AM. Commentary on "Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma." Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania, Philadelphia, PA: J Clin Oncol 2012;30(28):3545-51 [Epub 2012 Aug 27]. Urol Oncol 31(5):719, 2013. PMID: 23796204.
24. Kamat AM. Commentary on "The clinical epidemiology of urachal carcinoma: results of a large, population based study." Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA, Department of Urology, Radboud University Medical Centre, Utrecht, The Netherlands: J Urol 2012;188(4):1102-7 [Epub 2012 Aug 15]. Urol Oncol 31(5):720, 2013. PMID: 23796205.
25. Shah JB, Kamat AM. Fluorescence cystoscopy for nonmuscle invasive bladder cancer: is the honeymoon over for the blue light special?. Cancer 117(5):882-3, 2011. PMID: 20960505.
26. Kamat AM, Svatek R. Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of Progression and Metastasis in Patients With Newly Diagnosed T1 Bladder Urothelial Cancer. J Urol 182(6):2630; discussion 2631, 2009. PMID: 19836780.
27. Kamat AM. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. J Urol 182(5):2203, 2009. PMID: 19758663.
28. Kamat AM. Intravesical BCG for bladder cancer: how much is enough?. Cancer 113(4):674-6, 2008. PMID: 18543323.
29. Kamat AM, Fisher MB. Lymph node density: surrogate marker for quality of resection in bladder cancer?. Expert Rev Anticancer Ther 7(6):777-9, Jan-Feb, 2007. PMID: 17555386.
30. Kamat AM. Outcome of penile cancer in circumcised men. J Urol 175(2):561, 2006.
31. Kamat AM, Dinney CP. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Nat Clin Pract Urol 3(9):472-473, 2006.
32. Kamat AM. Neoadjuvant chemotherapy for invasive bladder cancer: a new standard of care?. Am J Clin Onc Rev 2(11):624-637, 2003.

Abstracts

1. Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo C, Navai N, Dinney C, Kamat AM. PD13-12: Bladder sparing treatment in patients with BCG unresponsive non-muscle invasive bladder cancer: An analysis of long-term survival outcomes. The Journal of Urology 209(4):e410, 2023.
2. Grajales V, Duan Z, Tan WS, Contieri R, Zhao H, Giordano S, Williams SB, Kamat AM. MP54-14: Mental health illness in patients with Non-Muscle Invasive Bladder Cancer. Does BCG play a role?. The Journal of Urology 209(4):e759, 2023.
3. Tan WS, Ahmad A, Nathan A, Ogunbo A, Gbolahan O, Kallam N, Tan WP, Cohen D, Volanis D, Kamat AM, Kelly J. PD29-01: The Hematuria Cancer Risk Score: A validation study demonstrating reduction in the number needed to investigate while preserving fidelity of cancer detection. The Journal of Urology 209(4):e824, 2023.
4. Lim A, Sood A, Narayan V, Seif M, Matulay J, Bree K, Campbell M, Kamat AM, Dinney C, Navai N. MP56-06: Pathologic Downstaging Rate and Predictive Biomarker Exploration in Patients with Biopsy-Proven Clinically Node Positive Bladder Cancer Undergoing Chemotherapy Followed by Radical Cystectomy. The Journal of Urology 209(4):e775, 2023.
5. Lobo N, Sood A, Duan Z, Tan WS, Grajales V, Lindskrog SV, Dyrskjot L, Denmark A, Zhao H, Giordano S, Williams SB, Kamat AM. PD29-05: Association of Age With Non-Muscle Invasive Bladder Cancer: A Biological Basis For Epidemiological Disparities?. The Journal of Urology 209(4):e826, 2023.
6. Kulkarni G, Richards K, Black PC, Rendon R, Chin J, Shore N, Jayram G, Kramolowsky E, Saltzstein D, Agarwal P, Belkoff L, O'Donnell M, Kamat AM, Zlotta A, Jewett MAS, Lamm D, DeGruttola V, Mandel A, Dumoulin-White RJ, Kassouf W. MP63-01: An Interim Analysis of a Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In- Situ (CIS). The Journal of Urology 209(4):e871, 2023.
7. Kulkarni GS, Kamat AM, Uchio EM, Roumiguie M, Krieger LEM, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, de Wit R, Kapadia E, Xing A, Fijlstra MVdS, Boormans JL. MP63-05: Outcomes in Patients (Pts) With Bacillus Calmette-Guerin (BCG)-Unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC) Who Underwent Radical Cystectomy (RC) Following Pembrolizumab (Pembro) Treatment in KEYNOTE-057 Cohort A. The Journal of Urology 209(4):e872, 2023.
8. Contieri R, Hensley P, Tan WS, Grajales V, Bree K, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. MP63-06: Bacillus Calmette-Guerin vs Immediate Radical Cystectomy in EAU De. AUA Journals, 2023.
9. Contieri R, Grajales V, Tan WS, Bree K, Hensley P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. MP63-11: Advanced Age (>70 Years) Does not A‰ect Oncological Outcomes in Non-Muscle Invasive Bladder Cancer Patients Treated with Adequate Bacillus Calmette-Guerin: A Competing Risk Analysis from a Tertiary Care Center. The Journal of Urology 209(4), 2023.
10. Contieri R, Tan WS, Grajales V, Bree K, Hensley P, Guo CC, Navai N, Dinney CP, Kamat AM. MP63-15: T1 Sub-staging is Associated with Worse Oncological Outcomes For Patients Treated with Bacillus Calmette-Guerin or Immediate Radical Cystectomy. The Journal of Urology 209(4):e877, 2023.
11. Kamat AM, Steinberg GD, Inman BA, Kates MR, Uchio EM, Porten SP, Roupret M, Redorta J, Catto JWF, Kulkarni GS, Powles T, Tyson M, Haas GP, Yu Y, Birrenkott M, Lotan Y. Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress. 2023 ASCO Genitourinary Cancers Symposium, 2023.
12. Kulkarni GS, Richards KA, Black PC, Rendon RA, Chin J, Shore ND, Jayram G, Kramolowsky EV, Saltzstein D, Agarwal PK, Belkoff L, O'Donnell MA, Kamat AM, Jewett MAS, Lamm DL, DeGruttola V, Mandel A, Dumoulin-White R, Kassouf W. A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis). 2023 ASCO Genitourinary Cancers Symposium, 2023.
13. Necchi A, Roumiguié M, Esen AA, Lebret T, De Wit R, ND Shore, Bajorin DF, Krieger LEM, Kandori S, Uchio EM, Seo HK, Boormans J, Kamat AM, Singer EA, Grivas P, Nishiyama H, Nam K, Kapadia E, Van den Sigtenhorst-Fijlstra M, Kulkarni GS. Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial. 2023 ASCO Genitourinary Cancers Symposium, 2023.
14. Necchi A, Roumiguié M, Esen AA, Lebret T, De Wit R, ND Shore, Bajorin DF, Krieger LEM, Kandori S, Uchio EM, Seo HK, Boormans J, Kamat AM, Singer EA, Grivas P, Nishiyama H, Nam K, Kapadia E, Van den Sigtenhorst-Fijlstra M, Kulkarni GS. LBA03-08: Pembrolizumab (pembro) for Patients (pts) With High-Risk Non-Muscle-Invasive Bladder Cancer (HR NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG): E‹cacy and Evaluation of Subsequent Cystectomy From Cohort B of the Phase 2 KEYNOTE-057 Study. Journal of Clinical Oncology 41(6), 2023.
15. Sood A, Rudzinski JK, Labbate, CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao JJ, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. 23rd Annual Meeting of the Society of Urologic Oncology (SUO), 2022.
16. Kulkarni GS, Kamat AM, Uchio EM, Roumiguie M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Wit E, Kapadia E, Nam K, Fijlstra MVS, Boormans JL. Pembrolizumab in Participants with Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer: 5-Year Follow-up From Cohort a of the Phase 2 Keynote-057 Trial. 23rd Annual Meeting of the Society of Urologic Oncology (SUO), 2022.
17. Mitra AP, Mokkapati S, Navai N, Kamat AM, McConkey DJ, Dinney CPN. Generation and Validation of a Predictive Urine-Microrna Signature for Intravesical BCG Therapy. 23rd Annual Meeting of the Society of Urologic Oncology (SUO), 2022.
18. Li R, Steinberg GD, Uchio EM, Lamm DL, Shah P, Kamat AM, Bivalacqua T, Packiam VT, Chisamore MJ, McAdory J, Grandi P, Hnat N, Burke J. CORE1: Phase 2 Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG). Journal of Clinical Oncology 40(16):4597, 2022.
19. Kukreja JB, Li R, Seif M, Wang X, Kamat AM, Dinney CP, Pisters LL, Navai N. A comparison of pathologic and intermediate term oncologic outcomes following open and robotic radical cystectomy. Journal of Clinical Oncology 37(7_suppl):440-440, 2019. e-Pub 2019.
20. De Wit R, Kulkarni GS, Uchio EM, Krieger LEM, Boormans JL, Roumiguié M, Singer EA, Bajorin DF, Kamat AM, Grivas P, Seo HK, Nishiyama H, Konety BR, Nam K, Kapadia E, Frenkl TL, Balar AV. Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): updated follow-up from KEYNOTE-057. Journal of Clinical Oncology 37(7_suppl):350-350, 2019. e-Pub 2019.
21. Ray-Zack MD, Shan Y, Kerr P, Kosarek CD, Hudgins HK, Jazzar U, Kaul S, Kamat AM, Tyler DS, Swanson TA, Mehta HB, Williams SB. Comparing Radical Cystectomy with Trimodal Therapy For Patients Diagnosed With Bladder Cancer: Critical Assessment of Statistical Methodology and Interpretation of Observational Data. Journal of Clinical Oncology 37(7_suppl):373-373, 2019. e-Pub 2019.
22. Ray-Zack MD, Shan Y, Kerr P, Kosarek CD, Hudgins HK, Jazaar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB, Williams SB. Comparing costs of Radical Cystectomy versus Trimodal Therapy for patients diagnosed with localized muscle-invasive bladder cancer. Journal of Clinical Oncology 37(15_suppl):e16021-e16021, 2019. e-Pub 2019.
23. AM Kamat, Shore ND, Hahn NM, Alanee SR, Nishiyama H, Shariat SF, Nam K, Kapadia E, Frenkl TL, Steinberg GD. Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: phase 3 KEYNOTE-676 study. Journal of Clinical Oncology 37(15_suppl):TPS4591-TPS4591, 2019. e-Pub 2019.
24. Gao JJ, Siefker-Radtke AO, Navai N, Campbell MT, Tidwell RS, Guo C, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Blando JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Allison JP, Dinney CP, Sharma P. A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). Journal of Clinical Oncology 36(15_suppl):e16524-e16524, 2018. e-Pub 2018.
25. Steinberg GD, Shore ND, Karsh LI, Bailen JL, Bivalacqua T, Chamie K, Cochran JS, David R, Grubb RL, Harb WA, Holzbeierlein JM, Kamat AM, Trabulsi EJ, Walsh WV, Williams MB, Wolk F, Woods M, Price ML, Early B, Schreiber TH. Immune response results from vesigenurtacel-I (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC). J Clin Oncol 35, 2017.
26. Li, R, Metcalfe MJ, Ferguson, III, JE, Gorantla S, Navai N, Shah JB, Grossman HB, Dinney CP, Kamat AM. Using Grade of Tumor Recurrence After BCG Therapy to Guide Further Therapy. American Urological Association Annual Meeting, 2017.
27. Kamat AM, Bellmunt J, Choueiri T, Nam K, De Santis M, Dreicer R, Hahn N, Perini R, Seifker-Radtke A, Sonpavde G, de Wit R, Witjes F, Keefe S, Bajorin D. KEYNOTE-057: Phase 2 study of pembrolizumab for patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). J Clin Oncol 34 (suppl; abstr TPS4576), 2016.
28. Kamat AM. Non Muscle Invading Micropapillary Urothelial Cancer - Immediate cystectomy, 2013.
29. Fernandez M, Gong Y, Ye Y, Chang D, Kamat AM, Wu X. Gamma-H2AX Level in Peripheral Blood Lymphocytes as a Risk Predictor for Bladder Cancer, 2013.
30. Kamat AM. Optimal timing of chemotherapy and cystectomy of muscle, 2013.
31. Fernandez M, Willis D, Dickstein R, Parikh S, Siefker-Radtke A, Guo C, Czerniak B, Shah J, Pisters L, Grossman H, Dinney C, Kamat AM. Clinical outcomes of patients with micropapillary bladder cancer treated with neoadjuvant therapy and/or radical cystectomy, 2013.
32. Porten S, Park A, Guo C, Xiao L, Kamat AM, Surena M. Does tumor size influence the accuracy of ureteroscopic biopsy for upper tract urothelial carcinoma?, 2013.
33. Willis D, Fernandez M, Dickstein R, Parikh S, Shah J, Pisters L, Guo C, Czerniak B, Grossman H, Dinney C, Kamat AM. Management of cT1 micropapillary bladder cancer, 2013.
34. Fernandez M, Willis D, Dickstein R, Parikh S, Siefker-Radtke A, Guo C, Czerniak B, Shah J, Pisters L, Grossman H, Dinney C, Kamat AM. Does the extent of micropapillary component impact clinical outcome?, 2013.
35. Kamat AM, Chang S, Lee C, Amiel G, Beard T, Fergany A, Kames J, Menon V, Sexton W, Slaton J, Svatek R, Wilson S, Techner L, Bihrle R, Koch M, Steinberg G. Alvimopan, a peripherally acting mu-opioid receptor antagonist, accelerates gastrointestinal recovery and decreases length of hospital stay after radical cystectomy, 2013.
36. Kamat AM. BCG Intravesical therpay: improving clinical outcomes and defining BCG failure, 2013.
37. Fernandez M, Willis D, Dickstein R, Parikh S, Siefker-Radtke A, Guo C, Czerniak B, Shah J, Pisters L, Grossman H, Dinney C, Kamat AM. Prognostic significance of p0 stage in patients with micropapillary bladder cancer undergoing radical cystectomy 189(4S):e215-e216, 2013.
38. R. J. Dickstein, H. B. Grossman, S. M. Pretzsch, J. A. Karam, R. E. Millikan, C. P. Dinney, Kamat AM. Can we reliably identify patients for radical cystectomy without neoadjuvant chemotherapy?. J Clin Oncol, 2011.
39. Dickstein RJ, Jinesh GG, Chunduru S, Kamat AM. Potential Role of Smac Mimetics as an Adjunct in BCG Failure Patients with Non-Muscle Invasive Bladder Cancer. American Urological Association Annual Meeting, 2011.
40. Karam JA, Shah JB, Kader AK, Svatek RS, Guo C, Grossman HB, Munsell M, Katz R, Dinney CP, Kamat AM. Prospective trial to identify optimal bladder cancer surveillance protocol: Reducing costs while maximizing sensitivity. 2010 Genitourinary Cancers Symposium, 2010.
41. Fernandez, M, Parikh S, Dinney, CP, Grossman HB, Katz R, Matin S, Kamat AM. The Role Of Fish In Upper Urinary Tract Surveillance After Radical Cystectomy For Bladder Cancer. American Urological Association Annual Meeting, 2010. PMID: 21396845.
42. Chiong, E, Hegarty, P, Davis, JW, Kamat AM, Pisters, LL, Matin, SF. Port-Site Hernias Occurring After The Use Of Bladeless Radially Expanding. American Urological Association Annual Meeting, 2010.
43. Williams M, Pircher T, Zomorrodi M, Mikolajczyk S, Kamat AM. Recovery Of Circulating Tumor Cells In Urothelial Carcinoma Cell Lines Utilizing A Novel Antibody Based Microfluidic Cell Capture Technique. American Urological Association Annual Meeting, 2010.
44. Karam J, Shah J, Kader K, Svatek R, Guo C, Grossman HB, Munsell M, Katz R, Dinney C, Kamat AM. Prospective Trial To Identify Optimal Bladder Cancer Surveillance Protocol: Reducing Costs While Maximizing Sensitivity. American Urological Association Annual Meeting, 2010. PMID: 21426474.
45. Messetti F, Anderson R, Martinez S, Nogueras Gonzalez G, Katz R, Khanna A, Grossman HB, Dinney C, Kamat AM. Prospective Clinical Trial To Evaluate Markers Of Response To Intravesical Therapy For Bladder Cancer:. American Urological Association Annual Meeting, 2010.
46. AO Siefker-Radtke, Kamat AM, DL William, NM Tannir, S Tu, LC Pagliaro, CP Dinney, RE Millikan. A Phase II rendomized four-regimen selection trial incorporating response for sequetial chemotherapy inmetastatic, unresectable urothelial cancer: Final results from the M.D. Anderson Cancer Center. Journal of Clinical Oncology 27(15S):251s, 2009.
47. Kassouf W. Agarwal PK, Herr HW, Munsell Mf, Spiess PE, Brown GA, Pisters LL, Grossman HB, Dinney CP, Kamat AM. TNM Nodal status versus lymph node density for prediction of disease-specific survival after radical cystectomy for bladder cancer. J Urol 177(4):551, 2007.
48. Spiess PE, Brown GA, Tannir NM, Tu SM, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Predicting Disease Progression in Patients with Viable Tumor at Post Chemotherapy RPLND. American Urological Association Annual Meeting, 2007.
49. Spiess PE, Tannir NM, Brown GA, Liu P, Kamat AM, Tu SM, Evans JG, Pister LL,. Recurrence in Patients with pNO at RPLND: Can we Predict which Patients are at Risk?. American Urological Association Annual Meeting, 2007.
50. Black PC, Kassouf W, Brown GA, Kamat AM, Nogueras GM, Munsell M, Siefker-Radtke AO, Millikan RE, Grossman HB, Dinney CPN. Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy. American Urological Association Annual Meeting, 2007.
51. Black PC, Wright JL, Brown GA, Gomez JA, Porter MP, Kamat AM, Dinney CPN, Lin DW. Differences in Survival Between patients with Sarcomatoid Carcinoma, Carcinosarcoma and Transitional Cell Carcinoma of the Bladder. American Urological Association Annual Meeting, 2007.
52. Agarwal PK, Kassouf W, Dinney CPN, Munsell MF, Spiess PE, Brown GA, Grossman HB, Herr HW, Kamat AM. TNM Nodal Status Versus Lymph Node Density for Prediction of Disease-Specific Survival After Radical Cystectomy for Bladder Cancer. American Urological Association Annual Meeting, 2007.
53. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Dinney, CPN, Kamat AM. A comparison of performance of TNM staging versus lymph node density in risk stratification of patients undergoing cystectomy for urothelial carcinoma. J Urol 175(4):1251, 2006.
54. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Dinney CPN, Millikan RE. Prospective evidence supporting the utility of neoadjuvant chemotherapy in small cell urothelial cancer: preliminary results from a phase II clinical trial at the M. D. Anderson Cancer Center. J Urol 175(4):1240, 2006.
55. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Dinney CPN, Kamat AM. Natural history of bladder cancer in patients with P0 disease at radical cystectomy. J Urol 175(4):1233, 2006.
56. Brown GA, Spiess PE, Bassett RL, Siefker-Radtke AO, Grossman HB, Dinney CPN, Kamat AM. Management of primary carcinomas of the male urethra. J Urol 175(4):463, 2006.
57. Brown GA, Spiess PE, Bassett RL, Grossman HB, Dinney CPN, Kamat AM. Contemporary management of primary carcinomas of the female urethra. J Urol 175(4):462, 2006.
58. Spiess PE, Kassouf W, Brown GA, Kamat AM, Gomez JA, Evans J, Pisters, LL. M. D. Anderson experience in the clinical management of growing teratoma syndrome. J Urol 175(4):448, 2006.
59. Spiess P, Evans J, Kamat AM, Wood C, Pettaway C, Dinney C, Pisters L. Chylous Ascites after Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. J Urol 173(4):197, 2006.
60. Kamat AM, Rosser C, Wen S, Cheung R, Lee A, Putman S, Pisters L. Body Mass Index Does Not Affect Outcome For Men Undergoing External-Beam Radiotherapy For Localized Prostate Cancer. j Urol 173(4):280, 2005.
61. Leibovici D, Kassouf W, Kamat AM, Pisters L, Pettaway C, Dinney C. Transurethral tumor resection versus partial cystecomy for bladder preservation for muscle invasive cancer. J Urol 173(4):303, 2005.
62. Kassouf W, Safe S, Abdelrahim M, Chintharlapalli S, Nelkin G, Kamat AM. Activity of novel agonists of peroxisome proliferator-activated receptor gamma (PPAR-gamma) against human transitional cell tumors. J Urol 173(4):211, 2005.
63. Kassouf W, Leibovici D, Dinney C, Grossman H, Kamat AM. Validation of the concept of lymph node density in a contemporary series of patients. J Urol 173(4):358, 2005.
64. Kassouf W, Leibovici D, Zhou X, Dinney C, Grossman H, Siefker-Radtke A, Pisters L, Swanson D, Kamat AM. Significance of lymph node positive disease in patients treated with neoadjuvant chemotherapy: Is adjuvant chemotherapy beneficial?. J Urol 173(4):358, 2005.
65. Kamat AM, Gee J, Grossman H, Dinney C, Siefer-Radtke A, Millikan R, Swanson D, Robinson T, Pisters L. Micropapillary Transitional Cell Carcinoma of the Bladder: A Retrospective Review of the Experience with 100 Consecutive Patients. J Urol 173(4):302, 2005.
66. Kamat AM, Gee J, Dinney C, Grossman H, Swanson D, Millikan R, Robinson T, Pisters L.. The Case for Early Cystectomy in Non-Muscle-Invasive Micropapillary Transitional Cell Carcinoma of the Bladder. J Urol 173(4):247, 2005. PMID: 16469571.
67. Jacobsohn K, Kamat AM, Troncoso P, Shen Y, Wen S, Babaian R. Validation of selection criteria used in predicting extraprostatic cancer extension in patients undergoing nerve-sparing radical prostatectomy. J Urol 173(4):186, 2005.
68. Highshaw R, Dinney C, Bermejo C, Nelkin G, Kamat AM. Isolation and Characterization of metastatic variants obtained by orthotopic recycling of the papillary human transitional cell carcinoma (rt4) cell line. J Urol 173(4):159, 2005.
69. Highshaw R, Nelkin G, Matin S, Kamat AM. Atorvastatin: Potential For Use as an Anti-Tumor Agent in Bladder Cancer. J Urol 173(4):161, 2005.
70. Khanna A, Fernandez R, Payne L, Zhang H, Bekele B, Kamat AM, Caraway N, Katz RL. Telomere length is more highly associated with urothelial cancer in urinary tract cytology specimens than DNA ploidy and bladder recurrence FISH test. American Society of Cytopathology Annual Scientific Meeting, 2004.
71. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): predictive factors for survival. J Urol 171(4):1787, 2004.
72. Kamat AM, Rosser CJ, Levy LB, Chichakli R, Pisters LL. Fluctuation of > 1.5 ng/ml in serum PSA more than 2 years after external-beam radiotherapy predicts for biochemical failure. J Urol 169(4):1719, 2003.
73. Kamat AM, Riggs D, Lamm DL. Anti-tumor activity of common antibiotics against superficial bladder cancer. J Urol 169(4):988, 2003. PMID: 15028437.
74. Bermejo C, Dinney C, Kamat AM, Kedar D, Mirabilis R, McConkey D, Elliott W, Bar-Eli M. Downstream signaling pathways and antiangiogenic effects of the pan-erbb tyrosine kinase inhibitor CI-1033 in a human bladder cancer cell line. J Urol 169(4):730, 2003.
75. Bermejo C, Sanchez-Ortiz R, Kamat AM, Daliani D, Pettaway C. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile carcinoma. J Urol 169(4):683, 2003.
76. Kamat AM, Kedar D, Bermejo C, Davis D, Radinsky R, Elliott W, Bar-Eli M, McConkey D, Dinney C. CI-1033, a pan-erbB tyrosine kinase antagonist, inhibits the growth of orthotopic bladder cancer tumors via direct effects on receptor phosphorylation and inhibition of angiogenesis. J Urol 169(4):504, 2003.
77. Kamat AM, Karashima T, Davis DW, Dinney CPN, McConkey DJ. The proteasome inhibitor PS-341 sensitizes drug-refractory human transitional cell tumors to gemcitabine. J Urol 169(4):495, 2003.
78. Kamat AM, Riggs DR, Lamm DL. Retrovirus mediated suicide gene therapy protects against tumor rechallenge in a murine bladder cancer model (MBT2). J Urol 163(4):118, 2000.
79. Kamat AM, DeHaven JI, Riggs DR, Pathak VK, Hu WS, Lamm DL. Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model. J Urol 64(4):119, 1999.
80. Kamat AM, DeHaven JI, Lamm DL. Cytotoxic effect of Nerium oleander extract on bladder cancer cells. J Urol 161(4):115, 1999.
81. DeHaven JI, Anderson MI, Kamat AM, Riggs DR, Hogan TF, Lamm DL. Combined and sequential paclitaxel-based chemosensitivity in renal cell adenocarcinoma cell lines. ASCO Program Proceedings, 1999.

Book Chapters

1. Williams SB & Kamat AM. Urothelial Carcinoma with Variant Histology: Sarcomatoid, Plasmacytoid, and Micropapillary. In: Rare Genitourinary Tumors. Springer, 2016.
2. Abel EJ, Kamat AM. Bladder Cancer. In: Atlas of Bladder Cancer. Springer: New York, 221, 2010.
3. Kamat AM, Nseyo UO. Dysuria. In: Five Minute Urology Consult. Lippincott: Philadelphia, 28-29, 2000.
4. Kamat AM. Laboratory investigation in urology. In: Urology for Primary Care Physicians. WB Saunders, 23-31, 1999.

Books (edited and written)

1. Ashish M. Kamat, Peter C. Black. Bladder Cancer: A Practical Guide. Ed(s) Ashish M. Kamat, Peter C. Black. 1. Springer, Cham, XVII, 471, 2021.

Letters to the Editor

1. Li R, Sylvester R, Dinney CP, Kamat AM. Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer 3: 147-148, 2017.
2. Kamat AM, Urbauer DL. Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward? Eur Urol 2016;69:201-2: The Goal: Individualized Bacillus Calmette-Guérin Therapy. Eur Urol 69: 203, 2016.
3. Williams SB, Kamat AM. Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60-9. Eur Urol.
4. Williams SB, Lamm DL, Kamat AM. Re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.050. Eur Urol 68: e127, 2015.
5. Amrhein J, Kamat AM, Morales A. Re: Jarow JP et al.: Clinical trial design for the development of new therapies for non-muscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop (Urology 2014;83:262-265). Urology 84: 494-5, 2014.
6. Kamat AM. To the Editor: Response to Barlow et al, Urol Oncol 2010. Urol Oncol.